Prekallikrein modulating compositions and methods of use thereof

Through compounds and methods targeting PKK, the problem that the prior art cannot effectively treat PKK-related diseases is solved, and the reduction and prevention of symptoms of inflammatory and thrombotic diseases is achieved.

CN118922540APending Publication Date: 2024-11-08ADARX PHARMACEUTICALS INC
View PDF 83 Cites 0 Cited by

Patent Information

Application Number
CN202280073696.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-09
Filing Date
2022-09-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments are not effective in curing inflammatory and thrombotic diseases associated with plasma prokalliklikrein (PKK), such as hereditary angioedema (HAE) and other conditions associated with dysregulation of the kallikrein pathway.

Method used

Provided is a compound and method for regulating or reducing the expression and activity of PKK, thereby alleviating or inhibiting the symptoms of related diseases, including the use of specific oligonucleotide sequences and compositions to target PKK, Inhibit its expression and activity.

Benefits of technology

Effectively alleviate or inhibit the symptoms of inflammatory and thrombotic diseases, such as edema, angioedema, swelling, thrombosis and embolization, providing treatment and prevention solutions for diseases such as HAE.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004821189220000191
    Figure BDA0004821189220000191
  • Figure BDA0004821189220000201
    Figure BDA0004821189220000201
  • Figure BDA0004821189220000211
    Figure BDA0004821189220000211
Patent Text Reader

Abstract

Some aspects of the present disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the present disclosure are useful for reducing expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the present disclosure are useful for reducing expression of PKK protein in a cell or animal.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 251,571, filed October 1, 2021; U.S. Provisional Application No. 63 / 252,554, filed October 5, 2021; U.S. Provisional Application No. 63 / 270,504, filed October 21, 2021; U.S. Provisional Application No. 63 / 283,175, filed November 24, 2021; and U.S. Provisional Application No. 63 / 287,969, filed December 9, 2021. The disclosures of each of the prior applications are considered part of the disclosure of the present application and are incorporated by reference in their entirety into the disclosure of the present application. Background Art Plasma prekallikrein (prekallikrein, PKK) is a glycoprotein involved in the surface-dependent activation of blood coagulation, fibrinolysis, kinin production and inflammation. PKK, encoded by the KLKB1 gene, is a precursor of plasma kallikrein (kallikrein, PK). PKK is present in plasma as a contact factor (contact factor), which forms a non-covalent complex with high molecular weight kininogen. PKK is converted into PK by factor XIIa (Factor XIIa) by cutting the internal Arg-Ile peptide bond. PK is a member of the kinin-kallikrein pathway, which is composed of several proteins that play a role in inflammation, blood pressure control, coagulation and pain. PK releases kinin from kininogen, and also produces plasmin from plasminogen. For example, plasma kallikrein cuts high molecular weight kininogen (high molecular weightkininogen, HMWK) to produce bradykinin. Kinins, especially bradykinin, go on to induce downstream effects including vasodilation and edema (see, e.g., Schmaier. J. Thromb. Haemost 14:28-39, 2016). Certain mutations in PKK cause PKK deficiency, also known as Fletcher factor deficiency, which is a rare coagulation deficiency characterized by a prolonged activated partial thromboplastin time (PTT). PKK deficiency is associated with inflammatory and thrombotic disorders. Mutations in PKK prevent the release of plasmin and kinins (e.g., bradykinin), and / or reduce fibrinolysis. This results in reduced vasodilation and increased clot formation, which in turn increases the likelihood of contracting inflammatory or thrombotic diseases. Patients with PKK deficiency are usually asymptomatic, but still exhibit prolonged activated PTT and are at risk for developing such diseases. Inflammatory conditions occur when the immune system mistakenly attacks the body's own cells or tissues. This causes abnormal inflammation, which can lead to chronic pain, redness, swelling, stiffness, and damage to otherwise healthy body tissues. Inflammatory diseases include a large number of disorders and conditions characterized by inflammation. Some examples include rheumatoid arthritis, allergies, asthma, autoimmune diseases, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, pre-perfusion injury, and transplant rejection. It is estimated that in the U.S., more than 1.36 million adults suffer from rheumatoid arthritis and 3 million suffer from inflammatory bowel disease. Thrombosis is the formation of blood clots in blood vessels, blocking the flow of blood through the circulatory system. When blood vessels are damaged, the body uses platelets and fibrin to form blood clots to prevent blood loss. Even when blood vessels are not damaged, in some cases, blood clots can also form in vivo. In healthy people, there is a steady-state balance between procoagulant (coagulation) power and anticoagulant and fibrinolytic power. Many genetic, acquired and environmental factors can make the balance tend to coagulation, leading to the pathological formation of thrombus in veins (e.g., deep vein thrombosis), the pathological formation of thrombus in arteries (e.g., myocardial infarction, ischemic stroke) or the pathological formation of thrombus in cardiac chambers. Thrombus can block blood flow at the formation site, or break away and cause embolism to block distant blood vessels (e.g., pulmonary embolism, embolic stroke). In the United States alone, about 900,000 people are affected by blood clots every year, and about 100,000 of these people will die from complications related to blood clots. Hereditary angioedema (HAE) is a rare inflammatory disease characterized by recurrent episodes of swelling around the head and limbs (Zuraw, BLM Engl. J. Med. 359: 1027-36, 2008). Attacks of angioedema occur at unpredictable frequencies and are usually concentrated in the skin, as well as the gastric mucosa, oropharyngeal mucosa, and laryngeal mucosa. Suffocation due to laryngeal swelling can lead to death. HAE is caused by a lack or dysfunction of the serine protease inhibitor C1-INH (Kaplan, AP et al. J. Allergy Clin. Immunol. 109: 195-209, 2002). C1-INH is the main inhibitor of coagulation factors 12 and 11 (factor 11) of the intrinsic coagulation pathway and plasma kallikrein (Gigli, I. et al. J. Immunol. 104: 574-581, 1970). C1-INH-mediated inhibition of plasma kallikrein and factor 12 leads to inactivation of the kallikrein pathway and reduced bradykinin (BK) levels. C1-INH deficiency or dysfunction leads to overproduction of BK, which is believed to be the mechanism of HAE attacks. Type III HAE is associated with mutations in the factor 12 gene encoding the coagulation protein factor 12 (Cichon, S. et al. Am. J. Hum. Genet. 79: 1098-1104, 2006). There is currently no cure for certain inflammatory conditions such as HAE, or thrombotic conditions associated with dysregulation of PKK or other members of the kallikrein pathway.Therefore, there is a need to find effective treatments for PKK-related diseases. SUMMARY OF THE INVENTION The disclosure provides the compound, composition and method for regulating the expression or activity of PKK. In certain embodiments, the compound, composition and method can be used for reducing the expression of PKK mRNA in cell or animal. In certain embodiments, the compound, composition and method can be used for reducing the amount of PKK protein in cell or animal. In certain embodiments, the animal suffers from an inflammatory or thrombotic disease, disorder or condition or its symptoms. In certain embodiments, the disease is hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. Some compounds, compositions and methods provided herein relate to reducing inflammatory or thrombotic diseases, disorders or conditions or their symptoms, or hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in animals. In certain embodiments, the compounds and compositions provided herein are potent and tolerable and inhibit PKK expression and are useful for treating, preventing, ameliorating, or slowing the progression of an inflammatory or thrombotic disease, disorder, or condition or a symptom thereof, or hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, or infarction. In certain embodiments, the compounds and compositions include one or more features effective for improving effectiveness. In certain embodiments, the compounds and compositions include one or more features effective for improving tolerance. In certain embodiments, the compounds and compositions include one or more features effective for targeting the compounds or compositions to cells or tissues. In certain embodiments, the compounds and compositions are more potent or have greater therapeutic value compared to compounds disclosed to the public. DETAILED DESCRIPTION OF THE INVENTION It should be understood that both the above summary of the invention and the following detailed description are exemplary and explanatory only and do not constitute limitations on the claimed embodiments. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, treatises, and GenBank, NCBI and other sequence reference records, are hereby expressly incorporated by reference to the portion of the documents discussed herein and in their entirety as of the filing date of this application. It should be understood that the sequence shown in each SEQ ID NO contained herein is independent of any modification of the sugar moiety, internucleoside linkage or nucleobase, even when shown in the context as a modified compound. Therefore, the compound defined by the SEQ ID NO may independently contain one or more modifications to the sugar moiety, internucleoside linkage or nucleobase. The oligomeric compounds cited by the Compound Number or Ref ID NO represent a combination of nucleobase sequences, chemical modifications and motifs. Here, unless otherwise expressly stated, the use of the singular includes the plural. For example, a noun used herein without a quantifier modifier refers to one or more than one (i.e., at least one) grammatical object. For example, "element" means one element or more than one element, such as a plurality of elements. Unless otherwise stated, the use of "or" used herein means "and / or". In addition, the use of the term "includes / comprising" and other forms (e.g., variations thereof) is not restrictive and can be used interchangeably with the phrase "including but not limited to". definition Unless otherwise stated, the following terms have the following meanings: "Plasma kallikrein" or "kallikrein B1," which are used interchangeably with the term "PKK," refer to any nucleic acid or protein of PKK. Exemplary nucleotide and amino acid sequences of PKK can be found, for example, in GenBank Accession No. NM_000892.5 (incorporated herein as SEQ ID NO: 1), NG_012095.2 truncated from 23529..54493 (incorporated herein as SEQ ID NO: 2), XM_0170081811 (incorporated herein as SEQ ID NO: 3), NC_000004.12 truncated from 186215714 to 186258477 (incorporated herein as SEQ ID NO: 4), NM_001318394.2 (incorporated herein as SEQ ID NO: 5), and NM_001318396.2 (incorporated herein as SEQ ID NO: 6). Other examples of PKK sequences are readily available through publicly available databases (e.g., GenBank, UniProt, and OMIM). Additional information about PKK can be found, for example, at ncbi.nlm.nih.gov / gene / ? term=PKK. PKK as used herein also refers to variations of the PKK gene, including variants provided in the SNP database. Many sequence variations within the PKK gene have been identified and can be found, for example, at NCBI dbSNP and UniProt (see, for example, ncbi.nlm.nih.gov / snp / ? term==PKK). "PKK mRNA" means mRNA encoding a PKK protein. PKK can be represented in uppercase or lowercase. "PKK specific inhibitor" refers to any agent that can specifically inhibit PKK RNA and / or PKK protein expression or activity at the molecular level. For example, PKK specific inhibitors include nucleic acids (including oligonucleotide compounds), peptides, antibodies, small molecules, and other agents that can inhibit the expression of PKK RNA and / or PKK protein. "2'-O-methoxyethyl" or "2'-MOE" means a 2'-O(CH2)2-OCH3 modification. A 2'-O-methoxyethyl modified sugar is a modified sugar having 2'-O(CH2)2-OCH3 in place of the 2'-OH group of the ribosyl ring. "5' initiation site" means the nucleotide of a target nucleic acid or region that aligns with the 3'-most nucleoside of an antisense oligonucleotide. "3' stop site" means the nucleotide of the target nucleic acid or region that is aligned with the 5'-most nucleoside of the antisense oligonucleotide. "About" means within ±10% of a value. For example, if the statement "the compound achieved about 70% inhibition of PKK" is used, it means that the PKK level is inhibited in the range of 60% to 80%. When "about" is present before a series of numbers or ranges, it should be understood that "about" can modify each number in the series or range. "Administering" and its variations refer to the route by which a compound or composition provided herein is introduced into an individual to achieve its intended function. For example, routes of administration that may be used include, but are not limited to, parenteral administration, such as subcutaneous, intravenous or intramuscular injection or infusion. "Improvement" refers to the improvement or alleviation of at least one indicator, sign or symptom of a disease, disorder or condition of interest. In certain embodiments, improvement includes delaying or slowing the progression or severity of one or more indicators of a condition or disease. The progression or severity of an indicator can be determined by subjective or objective measurements known to those skilled in the art. "Animal" refers to human and non-human animals, including but not limited to mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including but not limited to monkeys and chimpanzees. "Antisense oligonucleotide" or "antisense strand" means an oligonucleotide that contains a region complementary to a target nucleic acid (eg, PKK RNA or a region thereof). "Complementarity" about oligonucleotides means that when two core base sequences are aligned in opposite directions, such oligonucleotides or the core base sequence of one or more regions thereof are complementary to the core base sequence of another oligonucleotide or nucleic acid or one or more regions thereof. Unless otherwise indicated, the complementary core bases described herein are limited to the following pairings: adenine (A) and thymine (T), adenine (A) and uracil (U) and cytosine (C) and guanine (G). Complementary oligonucleotides and / or nucleic acids do not need to have core base complementarity at each nucleoside, and may include one or more core base mismatches. In contrast, "complete complementarity" or "100% complementary" about oligonucleotides means that such oligonucleotides have core base matches at each nucleoside without any core base mismatches. "Composition" or "pharmaceutical composition" means a mixture of substances suitable for administration to an individual. For example, a composition may include one or more compounds or salts thereof and a sterile aqueous solution. "Co-administration" means the administration of two or more compounds in any manner wherein the pharmacological effects of both compounds are manifested in the patient. Co-administration does not require that the two compounds be administered in a single pharmaceutical composition, in the same dosage form, by the same route of administration, or at the same time. The effects of the two compounds do not require that they manifest at the same time. The effects need only overlap for a period of time and do not need to be co-extended. Co-administration includes parallel or sequential administration of one or more compounds. "Conjugate group" means a group of atoms attached to an oligonucleotide. The conjugate group is optionally attached to the oligonucleotide via a conjugate linker. For example, the conjugate group may alter the distribution, targeting, or half-life of the compound into which it is incorporated. The conjugate group includes a targeting moiety. "Conjugation linker" means a group of atoms comprising at least one bond that connects a linking moiety to an oligonucleotide. "Identity" about an oligonucleotide means that the nucleobase sequence of such an oligonucleotide or one or more regions thereof matches that of another oligonucleotide or nucleic acid or one or more regions thereof. The identity of an oligonucleotide to another oligonucleotide or nucleic acid does not require that each nucleobase matches, and may comprise one or more different nucleobases. In contrast, "identical" or "100% identity" about an oligonucleotide means that such an oligonucleotide has the same nucleobase as the other oligonucleotide or nucleic acid at each relative position along its length. "Subject" means a human or non-human animal selected for treatment or therapy. "Inhibiting expression or activity" with respect to a target nucleic acid or protein means reducing or blocking the expression or activity of such a target relative to expression or activity in an untreated or control sample, and does not necessarily mean complete elimination of expression or activity. As used herein, the term "internucleoside linkage" is a covalent linkage between adjacent nucleosides in an oligonucleotide. As used herein, "modified internucleoside linkage" means any internucleoside linkage other than a phosphodiester internucleoside linkage. A "phosphorothioate internucleoside linkage" is a modified internucleoside linkage in which one of the non-bridging oxygen atoms of the phosphodiester internucleoside linkage is replaced by a sulfur atom. Representative internucleoside linkages with chiral centers include, but are not limited to, alkylphosphonates and phosphorothioates. Modified oligonucleotides comprising internucleoside linkages with chiral centers can be prepared as modified oligonucleotide groups comprising stereo-random internucleoside linkages, or as modified oligonucleotide groups comprising phosphorothioate linkages of specific stereochemical configurations, as further described below. Unless otherwise indicated, the chiral internucleoside linkages of the modified oligonucleotides described herein can be stereo-random or specific stereochemical configurations. The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. For example, the compounds may be treated with radioactive isotopes (e.g., tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C)) is radiolabeled. All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present disclosure. The term "isotopic variant" refers to a therapeutic agent (e.g., a compound and / or modified oligonucleotide disclosed herein) that contains an unnatural ratio of isotopes at one or more atoms that constitute the therapeutic agent. In certain embodiments, an "isotopic variant" of a therapeutic agent contains an unnatural ratio of one or more isotopes, including but not limited to hydrogen (H), deuterium ( 2 H), tritium ( 3 H), carbon-11 ( 11 C), carbon-12 ( 12 C), carbon-13 ( 13 C), carbon-14 ( 14 C), nitrogen-13 ( 13 N), nitrogen-14 ( 14 N), nitrogen-15 ( 15 N), oxygen-14 ( 14 O), oxygen-15 ( 15 O), oxygen-16 ( 16 O), oxygen-17 ( 17 O), oxygen-18 ( 18 O), fluorine-17 ( 17 F), fluorine-18 ( 18 F), phosphorus-31 ( 31 P), phosphorus-32 ( 32 P), phosphorus-33 ( 33 P), sulfur-32 ( 32 S), sulfur-33 ( 33 S), sulfur-34 ( 34 S), sulfur-35 ( 35 S), sulfur-36 ( 36 S), chlorine-35 ( 35 Cl), chlorine-36 ( 36 Cl), chlorine-37( 37 Cl), bromine-79( 79 Br), bromine-81( 81 Br), iodine 123( 123 I), iodine-125( 125 I), iodine-127( 127 I), iodine-129( 129 I) and iodine-131( 131 I). In certain embodiments, an "isotopic variant" of a therapeutic agent comprises unnatural proportions of one or more isotopes, including but not limited to hydrogen (H), deuterium ( 2 H), tritium ( 3 H), carbon-11 ( 11 C), carbon-12 ( 12 C), carbon-13 ( 13 C), carbon-14 ( 14C), nitrogen-13 ( 13 N), nitrogen-14 ( 14 N), nitrogen-15 ( 15 N), oxygen-14 ( 14 O), oxygen-15 ( 15 O), oxygen-16 ( 16 O), oxygen-17 ( 17 O), oxygen-18 ( 18 O), fluorine-17 ( 17 F), fluorine-18 ( 18 F), phosphorus-31 ( 31 P), phosphorus-32 ( 32 P), phosphorus-33 ( 33 P), sulfur-32 ( 32 S), sulfur-33 ( 33 S), sulfur-34 ( 34 S), sulfur-35 ( 35 S), sulfur-36 ( 36 S), chlorine-35 ( 35 Cl), chlorine-36 ( 36 Cl), chlorine-37( 37 Cl), bromine-79( 79 Br), bromine-81( 81 Br), iodine 123( 123 I), iodine-125( 125 I), iodine-127( 127 I), iodine-129( 129 I) and iodine-131( 131 I). It is understood that in a therapeutic agent (e.g., a compound and / or modified oligonucleotide disclosed herein), any hydrogen may be 2 H, or any carbon, for example, may be 13 C, or any nitrogen, for example 15 N, or any oxygen, for example, may be 18 O. In certain embodiments, an "isotopic variant" of a therapeutic agent comprises unnatural proportions of deuterium (D). "Mismatch" or "non-complementarity" means that when the first oligonucleotide / nucleic acid and the second oligonucleotide / nucleic acid are aligned in an antiparallel direction, the nucleobase of the first oligonucleotide or nucleic acid is non-complementary to the corresponding nucleobase of the second oligonucleotide or nucleic acid. For example, nucleobases, including but not limited to universal nucleobases, inosine and hypoxanthine, can hybridize with at least one nucleobase, but are still mismatched or non-complementary to the nucleobase to which it hybridizes. As another example, when the first oligonucleotide and the second oligonucleotide are aligned in an antiparallel direction, the nucleobase of the first oligonucleotide / nucleic acid that cannot hybridize with the corresponding nucleobase of the second oligonucleotide / nucleic acid is a mismatch or non-complementary nucleobase. "Modified oligonucleotide" means an oligonucleotide in which at least one sugar, nucleobase or internucleoside linkage is modified. "Regulate" refers to changing or adjusting a feature in a cell, tissue, organ, or organism. For example, regulating PKK RNA can mean increasing or decreasing the level of PKK RNA and / or PKK protein in a cell, tissue, organ, or organism. "Regulator" affects a change in a cell, tissue, organ, or organism. For example, a PKK compound can be a regulator that decreases the amount of PKK RNA and / or PKK protein in a cell, tissue, organ, or organism. "Motif" means the pattern of unmodified and modified sugar moieties, nucleobases and / or internucleoside linkages in an oligonucleotide. "Nucleic acid" refers to a molecule composed of monomeric nucleotides. Nucleic acids include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), single-stranded nucleic acid, and double-stranded nucleic acid. "Nucleobase" means a heterocyclic moiety capable of pairing with a base of another nucleic acid. "Naturally occurring nucleobases" as used herein are adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). "Modified nucleobases" are chemically modified naturally occurring nucleobases. "Universal bases" or "universal nucleobases" are nucleobases other than naturally occurring nucleobases and modified nucleobases, and are capable of pairing with any nucleobase. "Nucleobase sequence" means the order of consecutive nucleobases in a nucleic acid or oligonucleotide independent of any sugar or internucleoside linkages. "Nucleoside" means a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each independently unmodified or modified. "Modified nucleoside" means a nucleoside comprising a modified nucleobase and / or a modified sugar moiety. Modified nucleosides include abasic nucleosides lacking a nucleobase. "Oligomeric compound" means a compound comprising one or more oligonucleotides and optionally one or more additional features (e.g., conjugated groups or terminal groups). Examples of oligomeric compounds include single-stranded and double-stranded compounds, such as oligonucleotides, antisense oligonucleotides, interfering RNA compounds (RNAi compounds), microRNA targeting oligonucleotides, site-occupying compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds). RNAi compounds include double-stranded compounds (e.g., short interfering RNA (siRNA) and double-stranded RNA (dsRNA)) and single-stranded compounds (e.g., single-stranded siRNA (ssRNA), single-stranded RNAi (ssRNAi), short hairpin RNA (shRNA) and microRNA mimics), which act at least in part through the RNA-induced silencing complex (RISC) pathway, resulting in sequence-specific degradation and / or sequestration of target nucleic acids via a process known as RNA interference (RNAi). The term "RNAi compound" means other terms equivalent to those used to describe nucleic acid compounds capable of mediating sequence-specific RNA interference, such as interfering RNA (iRNA), iRNA agents, RNAi agents, short interfering oligonucleotides, short interfering nucleic acids, short interfering modified oligonucleotides, chemically modified siRNA, etc. Additionally, the term "RNAi" is intended to refer equivalently to other terms used to describe sequence-specific RNA interference. "Oligonucleotide" means a polymer of independently linked nucleosides, each of which may be modified or unmodified. The term "oligoduplex" means a duplex formed by two oligomeric compounds having complementary nucleobase sequences. Each oligomeric compound of an oligomeric duplex may be referred to as a "double-stranded oligomeric compound". The oligonucleotides of each oligomeric compound of an oligomeric duplex may include non-complementary protruding nucleosides. In some embodiments, the terms "double-stranded oligomeric compound" and "modified oligonucleotide" are used interchangeably. In other embodiments, the terms "oligoduplex" and "compound" are used interchangeably. "Parenteral administration" means administration by injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, such as intrathecal or intracerebroventricular administration. "Pharmaceutically acceptable carrier or diluent" means any substance suitable for administration to an individual. In certain embodiments, a pharmaceutically acceptable carrier or diluent facilitates administration of a compound to an individual and absorption by the individual, and may be included in the compositions of the present disclosure without causing significant adverse toxicological effects on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solution, and the like. For example, a pharmaceutically acceptable carrier may be a sterile aqueous solution, such as PBS or water for injection. Those skilled in the art will recognize that other pharmaceutical excipients may be used in the present disclosure. "Pharmaceutically acceptable salts" refers to physiologically and pharmacologically acceptable salts of compounds (eg, oligomeric compounds or oligonucleotides), ie, salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. As used herein, a pharmaceutically acceptable salt is any salt of a compound provided herein that retains its biological properties and is non-toxic or otherwise desirable for pharmaceutical use. Pharmaceutically acceptable salts of the therapeutic agents disclosed herein include salts prepared with relatively nontoxic acids or bases, depending on the particular substituents found in the compounds or modified oligonucleotides described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Thus, the compounds of the present disclosure may exist as salts, for example, with pharmaceutically acceptable acids. Such salts may be derived from a variety of organic and inorganic counterions known in the art. Such salts include, but are not limited to: (1) acid addition salts formed with organic or inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, pyruvic acid, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid , picric acid, cinnamic acid, mandelic acid, phthalic acid, lauric acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphoric acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, benzoic acid, glutamic acid, hydroxy or (2) salts formed when an acidic proton present in the parent compound undergoes (a) or (b) replacement by a metal ion, such as an alkali metal ion, an alkaline earth metal ion or an aluminum ion, or an alkali metal or alkaline earth metal hydroxide, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc and barium hydroxide, or ammonia; or (b) coordination with an organic base, such as an aliphatic, alicyclic or aromatic organic amine, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucaminepiperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like (see, e.g., Bergeet et al., 1996). al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19). Pharmaceutically acceptable salts also include, by way of example only and not limitation, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like, and, when the compound contains a basic functional group, non-toxic organic or inorganic acid salts such as hydrohalides, for example, hydrochlorides and hydrobromides, sulfates, phosphates, sulfamates, nitrates, acetates, trifluoroacetates, trichloroacetates, propionates, hexanoates, cyclopentylpropionates, glycolates, glutarates, pyruvates, lactates, malonates, succinates, sorbates, ascorbates, malates, maleates, fumarates, tartrates, citrates, benzoates, 3-(4-hydroxybenzoyl)benzoate, picrates, cinnamates, mandelates, phthalates, laurates, methanesulfonic acids. In some embodiments, the pharmaceutically acceptable salts of the compounds and modified oligonucleotides disclosed herein are sodium or potassium salts. In some embodiments, the pharmaceutically acceptable salts of the compounds and modified oligonucleotides disclosed herein are sodium salts. The compound of neutral form is preferably regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner. The parent form of the compound may be different from multiple salt forms in certain physical properties (such as solubility in polar solvents). In some embodiments, the compound of the present disclosure comprises both basic and acidic functional groups that allow the compound to be converted into base addition salts or acid addition salts. The compound of neutral form can be regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner. The parent form of the compound is different from multiple salt forms in certain physical properties (such as solubility in polar solvents), but, unless otherwise specified, the salt disclosed herein is equivalent to the parent form of the compound for the purpose of the present disclosure. "Pharmaceutical agent" means a chemical compound that provides a therapeutic benefit when administered to a subject. "Phosphorothioate linkage" means a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced by a sulfur atom. "Portion" means a determined number of consecutive (i.e., connected) core bases of a nucleic acid. In certain embodiments, a portion is a determined number of consecutive core bases of a target nucleic acid. In certain embodiments, a portion is a determined number of consecutive core bases of an oligonucleotide. "Prevention" means delaying or arresting for a period of time the onset, occurrence or progression of a disease, disorder or condition. "RNA interference compound" or "RNAi compound" means a compound that modulates a target nucleic acid and / or a protein encoded by a target nucleic acid at least in part through the RNA-induced silencing complex (RISC) pathway or Ago2 (rather than through RNase H). RNAi compounds include, but are not limited to, double-stranded siRNA, single-stranded siRNA, and microRNA, including microRNA mimics. "Sense oligonucleotide" or "sense strand" means the strand of a double-stranded compound that comprises a region that is substantially complementary to a region of the antisense strand of the compound. "Specific inhibition" with respect to a target nucleic acid or protein means reducing or blocking the expression or activity of the target nucleic acid or protein while minimizing or eliminating the effects on non-target nucleic acids or proteins. "Subunit" with respect to an oligonucleotide means a nucleotide, nucleoside, nucleobase or sugar, or a modified nucleotide, nucleoside, nucleobase or sugar as provided herein. "Target nucleic acid," "target RNA," and "nucleic acid target" all refer to a nucleic acid that can be targeted by the compounds described herein. "Target region" means a portion of a target nucleic acid to which one or more compounds are targeted. By "targeting moiety" is meant a conjugated group that provides enhanced affinity for a selected target (e.g., a molecule, cell or cell type, compartment (e.g., a cellular or organ compartment), tissue, organ, or body region) compared to, e.g., a compound without such a moiety. "Terminus group" means a chemical group or group of atoms covalently attached to the terminus of an oligonucleotide. "Therapeutically effective amount" or "effective amount" means the amount of a compound, medicament or composition that provides a therapeutic benefit to an individual. "Therapeutically effective amount" or "effective amount" is an amount sufficient for a compound to achieve the stated purpose (e.g., to achieve the effect for which it is administered, to treat, prevent or ameliorate a disease or to alleviate one or more symptoms of a disease or condition) relative to the absence of the compound. An example of a "therapeutically effective amount" or "effective amount" is an amount sufficient to help treat, prevent, ameliorate a disease or alleviate one or more symptoms of a disease. "Relief" of one or more symptoms (and grammatical equivalents of the phrase) means a reduction in the severity or frequency of one or more symptoms, or the elimination of one or more symptoms. A "prophylactically effective amount" of a drug is an amount of the drug that, when administered to a subject, will have the intended preventive effect, such as preventing or delaying the onset (or recurrence) of an injury, disease, pathological condition or condition, or reducing the likelihood of the onset (or recurrence) of an injury, disease, pathological condition or condition or its symptoms. As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic agent sufficient to provide a therapeutic benefit to an individual, such as treating, preventing or ameliorating a disease or condition or its symptoms as described above. For example, for a given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. The therapeutic effect can also be expressed as a "fold" increase or decrease. For example, a therapeutically effective amount can have an effect of at least 1.2 times, 1.5 times, 2 times, 5 times, or more relative to a control. The term "treat" and variations thereof refer to any sign of successful treatment or improvement of an injury, disease, pathological condition, or disorder, including any objective or subjective parameter, such as relief; remission; attenuation of symptoms or making an injury, pathological condition, or disorder more tolerable for the patient; slowing the rate of degeneration or decline; making the endpoint of degeneration less debilitating; improving the patient's physical or mental health. Treatment or improvement of symptoms can be based on objective or subjective parameters, including the results of a physical examination. The term "treat" and variations thereof may include prevention of an injury, pathological condition, disorder, or disease. In some embodiments, treatment is prevention. In some embodiments, treatment does not include prevention. As used herein, "treatment" or variations thereof (and as fully understood in the art) also broadly include any method for obtaining a beneficial or desired result (including a clinical result) in a subject's condition. Beneficial or desired clinical results may include, but are not limited to, alleviating or improving one or more symptoms or conditions, reducing the extent of the disease, stabilizing the disease state (i.e., not making it worse), preventing the spread or spread of the disease, delaying or slowing the progression of the disease, improving or alleviating the disease state, reducing the recurrence of the disease, and alleviating, whether partial or complete, and whether detectable or undetectable. In other words, "treatment" as used herein includes any cure, improvement, or prevention of a disease. Treatment may prevent the occurrence of a disease; inhibit the spread of a disease; alleviate the symptoms of a disease, completely or partially eliminate the potential causes of a disease, shorten the duration of a disease, or perform a combination of these events. As used herein, "treatment" and variations thereof include preventive treatment. Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein. The administration step may consist of a single administration, or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the composition used in the treatment, or a combination thereof. It should also be understood that the effective dose of the agent used for treatment or prevention may be increased or decreased over the course of a particular treatment or prevention regimen. In some cases, long-term administration may be required. For example, the composition is administered to a subject in an amount and duration sufficient to treat the patient. "Treatment" refers to the administration of a compound or pharmaceutical composition to an animal to effect an alteration or improvement of a disease, disorder or condition in the animal. Certain compounds of the present disclosure have asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms, which can be defined in terms of absolute stereochemistry as (R)- or (S)- or (D)- or (L)- (for amino acids), and individual isomers are all encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include compounds known in the art that are too unstable to be synthesized and / or isolated. The present disclosure is intended to include compounds in racemic and optically pure forms. Optically active (R)- and (S)- or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless otherwise specified, it is intended that the compounds include both E and Z geometric isomers. As used herein, the term "isomers" refers to compounds that have the same number and kind of atoms, and therefore the same molecular weight, but differ in the structural arrangement or configuration of the atoms. As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. It will be apparent to those skilled in the art that certain compounds of the present disclosure may exist in tautomeric forms and all such tautomeric forms of compounds are within the scope of the present disclosure. Unless otherwise stated, structures depicted herein are also intended to include all stereochemical forms of the structure (i.e., R and S configurations for each asymmetric center). Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the present disclosure. As used herein, "chiral enriched population" means a plurality of molecules of the same molecular formula, wherein the number or percentage of molecules in the population containing a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules expected to contain the same particular stereochemical configuration at the same particular chiral center in the population when the particular chiral center is stereo random. A population of chiral enriched molecules having multiple chiral centers in each molecule may include one or more stereo random chiral centers. In certain embodiments, the molecule is a modified oligonucleotide. In certain embodiments, the molecule is a compound comprising a modified oligonucleotide. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium or the replacement of carbon by an isotopically enriched 13 C or 14 Compounds having the present structures except for substitution of the carbon atoms at C are within the scope of the present disclosure. As used herein, "stereo-random chiral center" means a chiral center with a random stereochemical configuration in the context of a group of molecules with the same molecular formula. For example, in a group of molecules comprising a stereo-random chiral center, the number of molecules with the (S) configuration of the stereo-random chiral center may be, but not necessarily, the same as the number of molecules with the (R) configuration of the stereo-random chiral center. It is considered to be random when the stereochemical configuration of the chiral center is the result of a synthetic method that is not intended to control the stereochemical configuration. In certain embodiments, the stereo-random chiral center is a stereo-random phosphorothioate internucleoside linkage. Certain embodiments In certain aspects, the disclosure relates to methods, compounds and compositions for inhibiting PKK. In certain embodiments, PKK is specifically inhibited. In certain embodiments, PKK is specifically degraded. In certain embodiments, PKK expression is inhibited. In certain embodiments, PKK translation is inhibited. In certain embodiments, PKK activity is inhibited. In certain embodiments, relative to expression, translation or activity in untreated or control samples, PKK expression, translation or activity is reduced by at least 10%. For example, in certain embodiments, relative to expression, translation or activity in untreated or control samples, PKK expression, translation or activity is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, 10% to 50%, 25% to 50%, 25% to 75%, 50% to 75%, 50% to 99% or 75% to 99%. In certain embodiments, the expression, translation, or activity of PKK is reduced as measured by any suitable assay, including but not limited to an immunoassay, a hybridization-based assay, or a sequencing-based assay (e.g., RNA-Seq). In certain aspects, the disclosure relates to compounds targeting PKK nucleic acids. In certain embodiments, the PKK nucleic acids have the sequences shown in the following: GENBANK Accession No. NM_000892.5 (incorporated herein with SEQ ID NO: 1), NG_012095.2 truncated from 23529..54493 (incorporated herein with SEQ ID NO: 2), XM_017008181.1 (incorporated herein with SEQ ID NO: 3), NC_000004.12 truncated from 186215714 to 186258477 (incorporated herein with SEQ ID NO: 4), NM_001318394.2 (incorporated herein with SEQ ID NO: 5), and NM_0013183962 (incorporated herein with SEQ ID NO: 6). In certain embodiments, the compound is an oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. Certain embodiments provide compounds comprising a modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. Certain embodiments provide compounds comprising a modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627 and 628. Certain embodiments provide a compound comprising a modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 313, 626, 627 and 628. In certain embodiments, the modified oligonucleotide has a nucleobase sequence that is at least 80%, at least 85%, at least 90%, or at least 95% complementary to SEQ ID NO: 1, 3, 5, or 6. In certain embodiments, the modified oligonucleotide comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase. In certain embodiments, the compound is double-stranded. Certain embodiments provide compounds comprising: a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises: a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences provided in Tables 2 to 4, 6 and 8; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. Certain embodiments provide a compound comprising a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. Certain embodiments provide a compound comprising a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NO: 307, 312, or 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In certain embodiments, the modified oligonucleotide or the first modified oligonucleotide of any of the foregoing compounds has at least 80%, at least 85%, at least 90%, or at least 95% complementarity or identity with SEQ ID NO: 1, 3, 5, or 6 over its length. In certain embodiments, the modified oligonucleotide or the first modified oligonucleotide has at least 1, at least 2, or at least 3 mismatches with a region of SEQ ID NO: 1, 3, 5, or 6. In certain embodiments, the length of the complementary region between the first modified oligonucleotide or the first strand and the second modified oligonucleotide or the second strand is 14 to 30 linked nucleosides. In certain embodiments, the length of the complementary region between the first modified oligonucleotide or the first strand and the second modified oligonucleotide or the second strand is 14 to 23 linked nucleosides. In certain embodiments, the length of the complementary region between the first modified oligonucleotide or the first strand and the second modified oligonucleotide or the second strand is 19 to 23 linked nucleosides. In certain embodiments, the length of the complementary region between the first modified oligonucleotide or the first strand and the second modified oligonucleotide or the second strand is 21 to 23 linked nucleosides. In certain embodiments, the first modified oligonucleotide is fully complementary to the second modified oligonucleotide. In certain embodiments, the modified oligonucleotide or the first modified oligonucleotide of any of the aforementioned compounds comprises at least one modification selected from modified internucleoside linkage, modified sugar and modified nucleobase. In certain embodiments, the second modified oligonucleotide of any of the aforementioned compounds comprises at least one modification selected from modified internucleoside linkage, modified sugar and modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage. In certain embodiments, the phosphorothioate internucleoside linkage or the methylphosphonate internucleoside linkage is at the 3' end of the first or second modified oligonucleotide or at the 5' end of the first modified oligonucleotide. In certain embodiments, the modified sugar comprises a modification selected from the following: halogen, alkoxy and bicyclic sugar. In certain embodiments, the modified sugar comprises a 2'-F modification. In certain embodiments, the modified sugar comprises a 2'-OMe modification. In certain embodiments, each nucleoside of the first modified oligonucleotide comprises a modified sugar. In certain embodiments, each nucleoside of the second modified oligonucleotide comprises a modified sugar. In certain embodiments, the modified sugar comprises a modification selected from the group consisting of halogen, alkoxy, and bicyclic sugars, or a combination thereof. In certain embodiments, the modified sugar comprises a modification selected from the group consisting of 2'-MOE, 2'-F, and 2'-OMe, or a combination thereof. In certain embodiments, the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications. In certain embodiments, the second modified oligonucleotide comprises no more than five 2'-F sugar modifications. In certain embodiments, the compound described in any of the foregoing embodiments comprises a conjugated group. In certain embodiments, the conjugated group is connected to the 5' end of the modified oligonucleotide. In certain embodiments, the conjugated group is a targeting moiety. In certain embodiments, the targeting moiety comprises one or more GalNAc. In certain embodiments, the modified oligonucleotide is a second modified oligonucleotide or a sense oligonucleotide. In certain embodiments, one or more GalNAc is connected to the 2' or 3' position of the ribosyl ring. In certain embodiments, one or more GalNAc is connected to the 5' nucleoside of the modified oligonucleotide. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is selected from the following formula or a salt, solvate or hydrate thereof, wherein R is a part other than the 5' nucleoside in the modified oligonucleotide: In certain embodiments, R' is O. In certain embodiments, R' is S. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula I and R' is O. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula I and R' is S. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula II and R' is O. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula II and R' is S. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula III and R' is O. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula III and R' is S. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula IV and R' is O. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula IV and R' is S. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula V and R' is O. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is Formula V and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is S. Certain embodiments provide a compound comprising a first modified oligonucleotide selected from any one of Ref ID NO: IA0812 to 821; and a second modified oligonucleotide having a length of 14 to 21 linked nucleosides that is fully complementary to the first modified oligonucleotide. Certain embodiments provide compounds comprising a first modified oligonucleotide consisting of IA0813 and a second modified oligonucleotide consisting of IS1002. Certain embodiments provide compounds comprising a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1007. Certain embodiments provide compounds comprising a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1068. Certain embodiments provide a compound comprising a first modified oligonucleotide selected from any one of Ref ID NO: IA0864 to 866; and a second modified oligonucleotide having a length of 14 to 21 linked nucleosides that is fully complementary to the first modified oligonucleotide. Certain embodiments provide a compound comprising a first modified oligonucleotide selected from Ref ID NO: IA0818 and IA0864; and a second modified oligonucleotide selected from Ref ID NO: IS1058 and IS1059. Certain embodiments provide compounds comprising a first modified oligonucleotide consisting of IA0864 and a second modified oligonucleotide consisting of IS 1059. Certain embodiments provide compounds comprising a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1058. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0864 and a second modified oligonucleotide consisting of IS 1059. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1058. In certain embodiments, the compounds described in any of the preceding embodiments are in the form of pharmaceutically acceptable salts. In certain embodiments, the pharmaceutically acceptable salts are sodium salts. In certain embodiments, the pharmaceutically acceptable salts are potassium salts. In one aspect provided herein is a modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, Ref ID NO: IA0818 is a modified oligonucleotide according to the aforementioned chemical structure or a pharmaceutically acceptable salt or stereoisomer thereof. In one aspect provided herein is a modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, Ref ID NO: IS1058 is a modified oligonucleotide according to the aforementioned chemical structure or a pharmaceutically acceptable salt or stereoisomer thereof. In one aspect provided herein is a modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, Ref ID NO: IA0864 is a modified oligonucleotide according to the aforementioned chemical structure or a pharmaceutically acceptable salt or stereoisomer thereof. In one aspect provided herein is a modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, Ref ID NO: IS1059 is a modified oligonucleotide according to the aforementioned chemical structure or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the pharmaceutically acceptable salt of a modified oligonucleotide provided herein is a sodium salt or a potassium salt. In one aspect provided herein is a sodium salt of a modified oligonucleotide according to the following chemical structure: Or a stereoisomer thereof. In certain embodiments, Ref ID NO: IA0818 is a modified oligonucleotide according to the aforementioned chemical structure or a stereoisomer thereof. In one aspect provided herein is a sodium salt of a modified oligonucleotide according to the following chemical structure: In certain embodiments, Ref ID NO: IS1058 is a modified oligonucleotide according to the aforementioned chemical structure or a stereoisomer thereof. In one aspect provided herein is a sodium salt of a modified oligonucleotide according to the following chemical structure: Or a stereoisomer thereof. In certain embodiments, Ref ID NO: IA0864 is a modified oligonucleotide according to the aforementioned chemical structure or a stereoisomer thereof. In one aspect provided herein is a sodium salt of a modified oligonucleotide according to the following chemical structure: In certain embodiments, Ref ID NO: IS1059 is a modified oligonucleotide according to the aforementioned chemical structure or a stereoisomer thereof. In one aspect provided herein is a compound according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, compound No. RD2423 is a compound according to the aforementioned chemical structure or a pharmaceutically acceptable salt or stereoisomer thereof. In one aspect provided herein is a compound according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, compound No. RD2424 is a compound according to the aforementioned chemical structure or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the pharmaceutically acceptable salts of the compounds provided herein are sodium or potassium salts. In one aspect provided herein is the sodium salt of the compound according to the following chemical structure: In certain embodiments, compound No. RD2423 is a compound according to the aforementioned chemical structure or a stereoisomer thereof. In one aspect provided herein is the sodium salt of the compound according to the following chemical structure: In certain embodiments, compound number RD2424 is a compound according to the aforementioned chemical structure or a stereoisomer thereof. In certain embodiments, provided herein are populations of modified oligonucleotides, wherein all phosphorothioate internucleoside linkages of the modified oligonucleotides are stereo-irregular. In certain embodiments, provided herein are populations of compounds, wherein all phosphorothioate internucleoside linkages of the modified oligonucleotides are stereo-irregular. Certain embodiments provide a composition comprising a compound of any of the preceding embodiments and a pharmaceutically acceptable carrier. Certain embodiments provide a composition comprising a compound as described in any of the preceding embodiments for use in therapy. Certain embodiments provide a method for treating, preventing or improving a disease, disorder or condition associated with a kallikrein pathway of PKK and / or disorder in an individual, comprising administering a compound targeting PKK to an individual, thereby treating, preventing or improving the disease, disorder or condition. In certain embodiments, the compound or composition described in any of the foregoing embodiments is administered to an individual. In certain embodiments, the disease, disorder or condition is an inflammatory or thrombotic disease, disorder or condition or a symptom thereof. In certain embodiments, the disease, disorder or condition is hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound is administered to inhibit or alleviate or improve inflammatory or thrombotic disease, disorder or condition or a symptom thereof. In certain embodiments, administration of the compound inhibits or reduces or ameliorates hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction, or a symptom thereof. In certain embodiments, the compound described in any of the preceding embodiments or a composition comprising the compound is administered to an individual in a therapeutically effective amount. In certain embodiments, a composition comprising the compound described in any of the preceding embodiments is administered to an individual at a dosage level sufficient to deliver about 1 to 100 mg / kg of individual body weight. In certain embodiments, a compound described in any of the preceding embodiments or a composition comprising the compound is administered to an individual at a fixed dose of about 25 mg to about 1,000 mg. In certain embodiments, the compound or composition is administered to an individual once or more in a day at up to the dosage level or fixed dose. In certain embodiments, the composition comprising the compound described in any of the preceding embodiments is applied to an individual every day, every week, every month, every quarter or every year. In certain embodiments, the compound described in any of the preceding embodiments or the composition comprising the compound is applied to an individual about once a quarter (that is, once every three months) to about once a year. In certain embodiments, the compound described in any of the preceding embodiments or the composition comprising the compound is applied to an individual about once a quarter, about once every six months or about once a year. Certain embodiments provide a method for inhibiting PKK expression in a cell, comprising contacting a cell with a compound targeting PKK, thereby inhibiting the expression of PKK in the cell. In certain embodiments, the cell is in the liver of an individual. In certain embodiments, the individual suffers from or is at risk of suffering from an inflammatory or thrombotic disease, disorder or condition or a symptom thereof. In certain embodiments, the individual suffers from or is at risk of suffering from hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. Some embodiments provide a method for reducing or suppressing inflammatory or thrombotic diseases, disorders or illnesses or symptoms in an individual, including administering a compound targeting PKK to an individual, thereby reducing or suppressing inflammatory or thrombotic diseases, disorders or illnesses or symptoms in an individual. In certain embodiments, an individual suffers from or is in the following risk: hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, compound is a compound targeting PKK. In certain embodiments, compound is any one of the aforementioned compounds. In certain embodiments, compound or composition are administered parenterally. Some embodiments provide the compound of targeting PKK for treating, preventing or improving the purposes of the disease, obstacle or illness related to PKK. In certain embodiments, disease, obstacle or illness are inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, compound is the compound of targeting PKK. In certain embodiments, compound is any one of the aforementioned compounds. Some embodiments provide the compound of targeting PKK in the preparation for treating, preventing or improving the purposes of the medicine of the disease, obstacle or illness related to PKK.In certain embodiments, disease, obstacle or illness are inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.In certain embodiments, compound is the compound of targeting PKK.In certain embodiments, compound is any one of the aforementioned compounds. Certain indications In certain aspects, the disclosure relates to methods for inhibiting PKK expression, which can be used to treat, prevent or improve diseases, disorders or conditions associated with PKK in individuals by administering compounds targeting PKK. In certain embodiments, the compound can be a PKK specific inhibitor. In certain embodiments, the compound can be an antisense oligonucleotide, an oligomeric compound or an oligonucleotide targeting PKK. In certain aspects, the disclosure relates to treating, preventing or improving diseases, disorders or conditions associated with PKK. In certain embodiments, diseases, disorders or conditions associated with PKK that can be treated, prevented and / or improved by the methods provided herein include inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. Some compounds provided herein relate to such compounds and compositions, which reduce inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in animals. In certain embodiments, the method for treating, preventing or improving a disease, disorder or condition associated with PKK in an individual comprises administering a compound comprising a PKK specific inhibitor to the individual, thereby treating, preventing or improving the disease, disorder or condition. In certain embodiments, the individual is identified as suffering from the following or is at risk of suffering from the following: a disease, disorder or condition associated with PKK. In certain embodiments, the disease, disorder or condition is an inflammatory disease or a thrombotic disease. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 307, 312, and 626. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In certain embodiments, the length of the single-stranded compound can be 14 to 30, 14 to 23, 14 to 20, 16 to 20, or 14 to 16 connected nucleosides. In certain embodiments, the length of the single-stranded compound can be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 connected nucleosides. In certain embodiments, the double-stranded compound can include two oligonucleotides of the same or different lengths, as described elsewhere herein. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 connected nucleosides), which has a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 continuous nucleobases of any one of the nucleobase sequences of SEQ ID NO: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 connected nucleosides), which has a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide of 19 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound is administered parenterally to a subject. In certain embodiments, administration of the compound improves, maintains or prevents an inflammatory disease, a thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in an animal. In certain embodiments, the method for treating, preventing or improving inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in animals includes administering a compound comprising a PKK specific inhibitor to an individual, thereby treating, preventing or improving inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide. In certain embodiments, administration of the compound improves, maintains or prevents inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in animals. In certain embodiments, the individual is identified as having a disease associated with PKK or being at risk of having a disease associated with PKK. In certain embodiments, the method of suppressing PKK expression in an individual suffering from a disease, disorder or condition associated with PKK or in a risk of a disease, disorder or condition associated with PKK includes administering a compound comprising a PKK specific inhibitor to an individual, thereby suppressing the expression of PKK in the individual. In certain embodiments, the compound is administered to suppress the expression of PKK in the liver. In certain embodiments, the disease, disorder or condition is an inflammatory disease or a thrombotic disease. In certain embodiments, the individual suffers from or is at risk of: inflammatory disease, thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence selected from any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 307, 312, and 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide of 19 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound is administered parenterally to a subject. In certain embodiments, administration of the compound improves, maintains or prevents an inflammatory disease, a thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the method for suppressing the expression of PKK in the cell includes contacting the cell with a compound comprising a PKK specific inhibitor, thereby suppressing the expression of PKK in the cell. In certain embodiments, the cell is a hepatocyte. In certain embodiments, the cell is in the liver. In certain embodiments, the cell is in the liver of an individual suffering from or in the risk of suffering from: inflammatory disease, thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any one of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any one of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound includes a first modified oligonucleotide (e.g., a length of 14 to 30, such as a modified oligonucleotide of 14 to 23 connected nucleosides), which has a core base sequence comprising SEQ ID NO: 10 to 631 at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 continuous core bases; and a second modified oligonucleotide (e.g., a length of 14 to 30, such as a modified oligonucleotide of 14 to 23 connected nucleosides), which has a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide of 19 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide. In certain embodiments, a method of reducing or inhibiting an inflammatory disease, a thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, or infarction in an individual suffering from or at risk of suffering from a disease associated with PKK comprises administering to the individual a compound comprising a PKK-specific inhibitor, thereby reducing or inhibiting an inflammatory disease, a thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, or infarction in the individual. In certain embodiments, the individual suffers from or is at risk of suffering from an inflammatory disease, a thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide of 19 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound is administered parenterally to an individual. In certain embodiments, the individual is identified as having or being at risk of having a disease, disorder, or condition associated with PKK. Some embodiments relate to compounds comprising PKK specific inhibitors, which are used to treat diseases, disorders or conditions associated with PKK. In certain embodiments, disease, disorder or condition are inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, compound comprises the antisense oligonucleotides targeting PKK. In certain embodiments, compound comprises the oligonucleotides targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region of complementarity to the first modified oligonucleotide. In certain embodiments, the compound is administered parenterally to a subject. Certain embodiments relate to compounds comprising PKK specific inhibitors for alleviating or inhibiting inflammatory diseases, thrombotic diseases, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region of complementarity to the first modified oligonucleotide. Some embodiments relate to the use of compounds comprising PKK specific inhibitors for the manufacture or preparation of drugs for the treatment of diseases, disorders or conditions associated with PKK. Some embodiments relate to the use of compounds comprising PKK specific inhibitors for the preparation of drugs for the treatment of diseases, disorders or conditions associated with PKK. In certain embodiments, the disease is inflammatory or thrombotic disease. In certain embodiments, the disease is hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region of complementarity to the first modified oligonucleotide. Certain embodiments relate to compounds comprising PKK specific inhibitors for the manufacture or preparation of drugs for the treatment of inflammatory diseases or thrombotic diseases associated with PKK or in individuals at risk of inflammatory diseases or thrombotic diseases associated with PKK, or for the treatment of inflammatory diseases or thrombotic diseases. In certain embodiments, inflammatory diseases or thrombotic diseases are hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. Certain embodiments relate to compounds comprising PKK specific inhibitors for the preparation of drugs for the treatment of diseases associated with PKK. In certain embodiments, the disease is an inflammatory disease, a thrombotic disease, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction. In certain embodiments, the compound comprises an antisense oligonucleotide targeting PKK. In certain embodiments, the compound comprises an oligonucleotide targeting PKK. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide selected from the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising any one of SEQ ID NOs: 307, 312, and 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of any one of SEQ ID NOs: 307, 312, and 626.In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 307, 312, or 626. In certain embodiments, the compound comprises a modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of a nucleobase sequence of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 307, SEQ ID NO: 312, and SEQ ID NO: 626. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequence of SEQ ID NO: 468, SEQ ID NO: 611, SEQ ID NO: 616, SEQ ID NO: 619, and SEQ ID NO: 629. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 312 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 619. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 626 and a second modified oligonucleotide having a nucleobase sequence of SEQ ID NO: 629. In any of the foregoing embodiments, the compound may be single-stranded or double-stranded. In any of the foregoing embodiments, the compound may be an antisense oligonucleotide or an oligomeric compound. In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide having a length of 14 to 30, e.g., 14 to 23 linked nucleosides) having a region complementary to the first modified oligonucleotide.In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NO: 10 to 631; and a second modified oligonucleotide (e.g., a modified oligonucleotide of 14 to 30, e.g., 14 to 23 linked nucleosides in length) having a region complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NO: 10 to 631; and a second modified oligonucleotide of 19 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide. In any of the foregoing methods or uses, the compound can be an oligomeric compound. In any of the foregoing methods or uses, the compound can be single-stranded or double-stranded. In any of the foregoing methods or uses, the compound can target PKK. In certain embodiments, the compound comprises a modified oligonucleotide or consists of it. In certain embodiments, the compound comprises one or more modified oligonucleotides. In certain embodiments, the compound comprises a first modified oligonucleotide and a second modified oligonucleotide. In certain embodiments, the length of the modified oligonucleotide is 8 to 80 connected nucleosides, a length of 10 to 30 connected nucleosides, a length of 14 to 30 connected nucleosides, a length of 14 to 23 connected nucleosides, or a length of 19 to 23 connected nucleosides. In certain embodiments, the modified oligonucleotide is at least 80%, at least 85%, at least 90%, at least 95% or 100% complementary to any one of the nucleobase sequences recorded in SEQ ID NO: 1, 3, 5 or 6 in its length. In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar and / or at least one modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage. In certain embodiments, the modified sugar is a bicyclic sugar, 2'-MOE, 2'-F or 2'-OMe. In certain embodiments, the modified nucleobase is a 5-methylcytosine. In any of the foregoing embodiments, the length of each modified oligonucleotide is independently 12 to 30, 14 to 30, 14 to 25, 14 to 24, 14 to 23, 16 to 23, 17 to 23, 18 to 23, 19 to 23, 19 to 22 or 19 to 20 connected nucleosides. In certain embodiments, the modified oligonucleotide has at least 1, at least 2, at least 3 mismatches with the region of SEQ ID NO: 1, 3, 5 or 6. In any of the aforementioned methods or uses, the compound comprises the first and second modified oligonucleotides, wherein there is a complementary region between the first modified oligonucleotide and the second modified oligonucleotide. In certain embodiments, the length of the complementary region between the first oligonucleotide and the second oligonucleotide is 14 to 23, 19 to 23, or 21 to 23 connected nucleosides. In certain embodiments, the first modified oligonucleotide is completely complementary to the second modified oligonucleotide. In certain embodiments, the first modified oligonucleotide comprises at least one modification selected from modified internucleoside linkages, modified sugars, and modified nucleobases. In certain embodiments, the second modified oligonucleotide comprises at least one modification selected from modified internucleoside linkages, modified sugars, and modified nucleobases. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage. In certain embodiments, the modified internucleoside linkage is at the 3' end of the first or second modified oligonucleotide or at the 5' end of the first or second modified oligonucleotide. In certain embodiments, the first or second modified oligonucleotide comprises one or more modified sugars. In certain embodiments, each nucleoside of the first or second modified oligonucleotide comprises a modified sugar. In certain embodiments, the modified sugar comprises a modification selected from the following: halogen, alkoxy and bicyclic sugar. In certain embodiments, the modified sugar comprises a modification selected from the following: 2'-MOE, 2'-F and 2'-OMe or a combination thereof. In certain embodiments, the first or second modified oligonucleotide comprises no more than ten 2'-F sugar modifications. In certain embodiments, the first or second modified oligonucleotide comprises no more than five 2'-F sugar modifications. In any of the foregoing methods or uses, the compound comprises a conjugated group. In certain embodiments, the conjugated group is connected to the 5' end of the modified oligonucleotide. In certain embodiments, the conjugated group is a targeting moiety. In certain embodiments, the targeting moiety comprises one or more GalNAc. In certain embodiments, one or more GalNAc is connected to the 2' or 3' position of the ribosyl ring. In certain embodiments, one or more GalNAc is connected to the 5' nucleoside of the modified oligonucleotide. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is selected from Formula I to VIII, or a salt, solvate or hydrate thereof, wherein R is a modified oligonucleotide other than the 5' nucleoside. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula III and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula III and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula IV and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula IV and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula V and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula V and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula VI and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula VI and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula VII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula VII and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of formula VIII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is of Formula VIII and R' is S. In any of the aforementioned methods or uses, the compound comprises a first modified oligonucleotide selected from any one of Ref ID NO: IA0812 to 821, and a second modified oligonucleotide of 14 to 21 linked nucleosides in length, which is fully complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0813 and a second modified oligonucleotide consisting of IS1002. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1007. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1068. In any of the aforementioned methods or uses, the compound comprises a first modified oligonucleotide selected from any one of Ref ID NO: IA0864 to 866; and a second modified oligonucleotide of 14 to 21 linked nucleosides in length, which is fully complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0864 and a second modified oligonucleotide consisting of IS1059. Certain embodiments provide a compound comprising a first modified oligonucleotide selected from Ref ID NO: IA0818 and IA0864 and a second modified oligonucleotide selected from Ref ID NO: IS1058 and IS1059. Certain embodiments provide a compound comprising a first modified oligonucleotide consisting of IA0864 and a second modified oligonucleotide consisting of IS1059. Certain embodiments provide a compound comprising a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1058. In certain embodiments, the compound comprises a first modified oligonucleotide selected from Ref ID NO: IA0818 and IA0864 and a second modified oligonucleotide selected from Ref ID NO: IS1058 and IS1059. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0864 and a second modified oligonucleotide consisting of IS1059. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0818 and a second modified oligonucleotide consisting of IS1058. In certain embodiments, the compound is in the form of a pharmaceutically acceptable salt. In certain embodiments, the pharmaceutically acceptable salt is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt is a potassium salt. In certain embodiments, the composition comprises a compound as described in any one of the preceding embodiments and a pharmaceutically acceptable carrier. In any of the foregoing methods or uses, the compound described in any of the foregoing embodiments or a composition comprising the compound is administered to an individual in a therapeutically effective amount. In certain embodiments, the compound described in any of the foregoing embodiments or a composition comprising the compound is administered to an individual at a dosage level sufficient to deliver about 1 to 100 mg / kg of individual body weight. In certain embodiments, the compound described in any of the foregoing embodiments or a composition comprising the compound is administered to an individual at a fixed dose of about 25 mg to about 1,000 mg. In certain embodiments, the composition is administered to an individual once or more in a day at up to the dosage level or fixed dose. In any of the foregoing methods or uses, the compound described in any of the foregoing embodiments or the composition comprising the compound is applied to the individual every day, every week, every month, every quarter or every year. In certain embodiments, the compound described in any of the foregoing embodiments or the composition comprising the compound is applied to the individual about once a quarter (that is, once every three months) to about once a year. In certain embodiments, the compound described in any of the foregoing embodiments or the composition comprising the compound is applied to the individual about once a quarter, about once every six months or about once a year. Certain compounds In certain aspects, the disclosure relates to compounds comprising or consisting of an oligomeric compound.In certain embodiments, the oligomeric compound comprises a nucleobase sequence that is complementary to a nucleobase sequence of a target nucleic acid. In certain aspects, the disclosure relates to compounds comprising or consisting of a modified oligonucleotide.In certain embodiments, the modified oligonucleotide has a nucleobase sequence that is complementary to a nucleobase sequence of a target nucleic acid. In certain aspects, the disclosure relates to compounds comprising or consisting of antisense oligonucleotides.In certain embodiments, the antisense oligonucleotide has a nucleobase sequence that is complementary to a nucleobase sequence of a target nucleic acid. In certain aspects, the disclosure relates to compounds that are single-stranded compounds. In certain embodiments, the single-stranded compounds include or consist of oligomeric compounds. In certain embodiments, such oligomeric compounds include or consist of oligonucleotides and optionally conjugated groups. In certain embodiments, the oligonucleotides are modified oligonucleotides. In certain embodiments, the oligonucleotides are antisense oligonucleotides. In certain embodiments, the oligonucleotides of the single-stranded compounds or modified oligonucleotides include self-complementary core base sequences. In certain aspects, the disclosure relates to a compound that is a double-stranded compound. In certain embodiments, the double-stranded compound comprises an oligomeric compound or is composed of an oligomeric compound. In certain embodiments, the double-stranded compound comprises a first oligonucleotide and a second oligonucleotide. In certain embodiments, the first oligonucleotide has a region complementary to the target nucleic acid, and the second oligonucleotide has a region complementary to the first modified oligonucleotide. In certain embodiments, the double-stranded compound comprises a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a region complementary to the target nucleic acid. In certain embodiments, the double-stranded compound comprises a first modified oligonucleotide and a second modified oligonucleotide. In certain embodiments, the first modified oligonucleotide has a region complementary to the target nucleic acid, and the second modified oligonucleotide has a region complementary to the first modified oligonucleotide. In certain embodiments, the oligonucleotide or modified oligonucleotide of the double-stranded compound is an RNA oligonucleotide. In such embodiments, the thymine nucleobase in the modified oligonucleotide is replaced by a uracil nucleobase. In certain embodiments, the compound described herein comprises a conjugated group. In certain embodiments, the first oligonucleotide or the first modified oligonucleotide of the double-stranded compound comprises a conjugated group. In certain embodiments, the second oligonucleotide or the second modified oligonucleotide of the double-stranded compound comprises a conjugated group. In certain embodiments, the first oligonucleotide or the first modified oligonucleotide and the second oligonucleotide or the second modified oligonucleotide of the double-stranded compound each comprise a conjugated group. In certain embodiments, the length of the compound is 14 to 30 connected nucleosides. In certain embodiments, the length of the first oligonucleotide or the first modified oligonucleotide of the double-stranded compound is 14 to 30 connected nucleosides. In certain embodiments, the length of the second oligonucleotide or the second modified oligonucleotide is 14 to 30 connected nucleosides. In certain embodiments, the oligonucleotide or the modified oligonucleotide of the double-stranded compound is flat-ended at one end or both ends of the compound. In certain embodiments, the oligonucleotide or the modified oligonucleotide of the double-stranded compound comprises non-complementary protruding nucleosides at one end or both ends of the compound. In certain embodiments, the compound has a nucleobase sequence comprising at least 14 consecutive nucleobases of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, one of the oligonucleotides or modified oligonucleotides of the double-stranded compound has a nucleobase sequence comprising at least 14 consecutive nucleobases of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. Some examples of single-stranded and double-stranded compounds include, but are not limited to, oligonucleotides, antisense oligonucleotides, siRNAs, microRNA targeting oligonucleotides, site-occupying based compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds), and single-stranded RNAi compounds (e.g., small hairpin RNA (shRNA), single-stranded siRNA (ssRNA), and microRNA mimics). In certain embodiments, the compounds described herein have a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of a target region of a target nucleic acid to which it is targeted. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 12 to 30. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 12 to 23. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 14 to 30. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 14 to 23. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 15 to 30. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 15 to 23. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 16 to 30. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 16 to 23. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 17 to 30. In certain embodiments, the compounds described herein include oligonucleotides of subunits connected in length from 17 to 23. In certain embodiments, the compound described herein comprises an oligonucleotide of a subunit of 18 to 30 connections in length. In certain embodiments, the compound described herein comprises an oligonucleotide of a subunit of 18 to 23 connections in length. In certain embodiments, the compound described herein comprises an oligonucleotide of a subunit of 19 to 30 connections in length. In certain embodiments, the compound described herein comprises an oligonucleotide of a subunit of 19 to 23 connections in length. In other words, such oligonucleotides are respectively 12 to 30 subunits connected, 12 to 23 subunits connected, 14 to 30 subunits connected, 14 to 23 subunits connected, 15 to 30 subunits connected, 15 to 23 subunits connected, 16 to 30 subunits connected, 16 to 23 subunits connected, 17 to 30 subunits connected, 17 to 23 subunits connected, 18 to 30 subunits connected, 18 to 23 subunits connected, 19 to 30 subunits connected or 19 to 23 subunits connected. In certain embodiments, the compounds described herein comprise oligonucleotides of 14 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 16 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 17 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 18 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 19 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 20 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 21 connected subunits in length.In certain embodiments, the compounds described herein comprise oligonucleotides of 22 connected subunits in length. In certain embodiments, the compounds described herein comprise oligonucleotides of 23 connected subunits in length. In other embodiments, the compounds described herein comprise oligonucleotides of 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 23, 18 to 24, 18 to 25, 18 to 50, 19 to 23, 19 to 30, 19 to 50, 20 to 23, or 20 to 30 connected subunits. In certain such embodiments, the compounds described herein comprise an oligonucleotide of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 linked subunits in length, or a range bounded by any two of the foregoing values. In certain embodiments, the compound may also include additional moieties, such as conjugated groups or delivery moieties. In certain embodiments, such compounds are oligomeric compounds, and the additional moieties are connected to oligonucleotides. In certain embodiments, the conjugated groups are connected to the nucleosides of oligonucleotides. In certain embodiments, the compound may be shortened or truncated. For example, one or more subunits may be missing from the 5' end (5' truncation) or alternatively from the 3' end (3' truncation) of the oligonucleotide. In some embodiments, the compound can be extended. For example, one or more subunits can be attached to the 3' end or the 5' end of the oligonucleotide. In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 In some embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 In some embodiments, the subunit is connected to the 3' end of the two oligonucleotides of the double-stranded compound (for example, the subunit is connected to the 3' end of one of the oligonucleotides, and the subunit is connected to the 5' end of the other oligonucleotide). In some embodiments, when the subunit is connected to the two oligonucleotides of the double-stranded compound at the same end, the number of subunits connected to each oligonucleotide may be the same or different. In some embodiments, when the subunit is connected to the two oligonucleotides of the double-stranded compound at the same end, the number of subunits connected to each oligonucleotide is the same. In some embodiments, when the subunit is connected to the two oligonucleotides of the double-stranded compound at the same end, the number of subunits connected to each oligonucleotide is different. The situation in which the subunit is connected to the two oligonucleotides of the double-stranded compound at the same end can occur at one end or both ends of the double-stranded compound. In some embodiments, the subunit connected to the 3' and / or 5' end is modified. In certain embodiments, the compounds described herein are oligonucleotides. In certain embodiments, the compounds described herein are modified oligonucleotides. In certain embodiments, the compounds described herein are antisense oligonucleotides. In certain embodiments, the compounds described herein are oligomeric compounds. In certain embodiments, the compounds described herein are RNAi compounds. In certain embodiments, the compounds described herein are siRNA compounds. In certain embodiments, the compounds described herein may comprise any of the oligonucleotide sequences targeting PKK described herein. In certain embodiments, the compounds may be double-stranded. In certain embodiments, the compound comprises an oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of any one of SEQ ID NOs: 10 to 313, 626, 627, and 628. In certain embodiments, the compound comprises an oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of SEQ ID NOs: 307, 312, or 626. In certain embodiments, the compound comprises a second oligonucleotide. In certain embodiments, the compound comprises an oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of SEQ ID NO: 468, 611, 616, 619, or 629. In certain embodiments, the compound comprises a first oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of SEQ ID NO: 312 and a second oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of SEQ ID NO: 619. In certain embodiments, the compound comprises a first oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of SEQ ID NO:626 and a second oligonucleotide comprising a portion of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases of SEQ ID NO:629. In certain embodiments, the compound comprises ribonucleotides, wherein for any sequence provided herein, the oligonucleotide has uracil (U) instead of thymine (T). In certain embodiments, the compound comprises deoxyribonucleotides, wherein for any sequence provided herein, the oligonucleotide has thymine (T) instead of uracil (U). Some mechanisms In certain embodiments, the compound described herein comprises modified oligonucleotides or consists of modified oligonucleotides. In certain embodiments, the compound described herein comprises antisense oligonucleotides or consists of antisense oligonucleotides. In certain embodiments, the compound comprises an oligomeric compound or consists of an oligomeric compound. In certain embodiments, the compound described herein can hybridize with a target nucleic acid. In certain embodiments, the compound described herein selectively affects one or more target nucleic acids. Such a compound comprises such a core base sequence: hybridize with one or more target nucleic acids to produce one or more desired activities, and not hybridize with one or more non-target nucleic acids, or not hybridize with one or more non-target nucleic acids in such a way that causes significant undesirable activity. In certain embodiments, the hybridization of the compound described herein with the target nucleic acid results in the recruitment of one or more proteins causing the cutting of the target nucleic acid. For example, some compounds described herein or a portion of the compound are loaded into the RNA-induced silencing complex (RISC), ultimately resulting in the cutting of the target nucleic acid. For example, some compounds described herein cause the target nucleic acid to be cut by Argonaute. The compound loaded into RISC is an RNAi compound. The RNAi compound can be double-stranded (siRNA) or single-stranded (ssRNA). In certain embodiments, the hybridization of compound described herein and target nucleic acid will not result in the recruitment of proteins that cut target nucleic acid.In certain such embodiments, the hybridization of compound and target nucleic acid results in the change of target nucleic acid montage.In certain embodiments, the hybridization of compound and target nucleic acid results in the inhibition of binding interaction between target nucleic acid and protein or other nucleic acids.In certain such embodiments, the hybridization of compound and target nucleic acid results in the change of RNA processing.In certain such embodiments, the hybridization of compound and target nucleic acid results in the change of target nucleic acid translation. The activity produced by hybridization of the compound to the target nucleic acid can be observed directly or indirectly. In certain embodiments, the observation or detection of activity involves observing or detecting a change in the amount of a target nucleic acid or a protein encoded by such a target nucleic acid, a change in the ratio of a splice variant of a nucleic acid or protein, and / or a phenotypic change in a cell or animal. Some modifications In certain aspects, the disclosure relates to compounds comprising or consisting of oligonucleotides. Oligonucleotides are composed of linked nucleosides. In certain embodiments, the oligonucleotide can be unmodified RNA or DNA, or can be modified. In certain embodiments, the oligonucleotide is a modified oligonucleotide. In certain embodiments, relative to unmodified RNA or DNA, the modified oligonucleotide comprises at least one modified sugar, modified nucleobase or modified internucleoside linkage. In certain embodiments, the oligonucleotide has a modified nucleoside. The modified nucleoside may comprise a modified sugar, a modified nucleobase or both a modified sugar and a modified nucleobase. The modified oligonucleotide may also include terminal modifications, such as 5'-terminal modifications and 3'-terminal modifications. Sugar modifications and motifs In certain embodiments, the modified sugar is a substituted furanosyl sugar or a non-bicyclic modified sugar. In certain embodiments, the modified sugar is a bicyclic or tricyclic modified sugar. In certain embodiments, the modified sugar is a sugar surrogate. The sugar surrogate may comprise one or more substitutes described herein. In certain embodiments, the modified sugar is a substituted furanosyl or non-bicyclic modified sugar. In certain embodiments, the furanosyl sugar is a ribosyl sugar. In certain embodiments, the furanosyl sugar comprises one or more substituents, including but not limited to substituents at the 2', 3', 4' and 5' positions. In certain embodiments, substituents at the 2' position include, but are not limited to, F and OCH3 ("OMe", "O-methyl" or "methoxy"). In certain embodiments, substituents suitable for the 2' position of non-bicyclic modified sugars include, but are not limited to, halogen, allyl, amino, azido, SH, CN, OCN, CF3, OCF3, F, Cl, Br, SCH3, SOCH3, SO2CH3, ONO2, NO2, N3, and NH2. In certain embodiments, substituents at the 2' position include, but are not limited to, O-(C1-C 10 ) alkoxy, alkoxyalkyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, O-alkyl-O-alkyl, alkynyl, wherein alkyl, alkenyl and alkynyl can be substituted or unsubstituted C1 to C 10 Alkyl or C2 to C 10In some embodiments, the substituents at the 2' position include, but are not limited to, alkaryl, aralkyl, O-alkaryl, and O-aralkyl. In some embodiments, these 2' substituents may be further substituted with one or more substituents independently selected from the following: hydroxyl, alkoxy, carboxyl, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl, and alkynyl. In some embodiments, the substituents at the 2' position include, but are not limited to, O[(CH2) n O] m CH3, O(CH2) n OCH3, O(CH2) n CH3, O(CH2) n ONH2、O(CH2) n NH2, O(CH2) n SCH3 and O(CH2) n ON[(CH2) n CH3)] 2, wherein n and m are independently 1 to about 10. In certain embodiments, the substituent at the 2' position includes, but is not limited to, OCH2CH2OCH3 ("MOE"), O(CH2)2ON(CH3)2 ("DMAOE"), O(CH2)2O(CH2)2N(CH3)2 ("DMAEOE"), and OCH2C(=O)-N(H)CH3 ("NMA"). In certain embodiments, the substituents at the 4' position suitable for non-bicyclic modified sugars include but are not limited to alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015 / 106128. In certain embodiments, the substituents at the 5' position suitable for non-bicyclic modified sugars include but are not limited to methyl ("Me") (R or S), vinyl, and methoxy. In certain embodiments, the substituents described herein at 2', 4', and 5' positions may be added to other specific positions on the sugar. In certain embodiments, such substituents may be added to the 3' position of the sugar on the 3' end nucleoside or the 5' position of the 5' end nucleoside. In certain embodiments, non-bicyclic modified sugars may include more than one non-bridging sugar substituent. In certain such embodiments, non-bicyclic modified sugar substituents include but are not limited to 5'-Me-2'-F, 5'-Me-2'-OMe (including both R and S isomers). In certain embodiments, modified sugar substituents include those described in Migawa et al., WO 2008 / 101157 and Rajeev et al., US 2013 / 0203836. In certain embodiments, modified sugar is a bicyclic sugar. Bicyclic sugar is a modified sugar comprising two rings, wherein the second ring is formed by connecting the bridge of two atoms in the first ring, thereby forming a bicyclic structure. In certain embodiments, bicyclic sugar comprises two atoms of a bridging furanose base ring to form a bridging substituent of the second ring. In certain embodiments, bicyclic sugar does not comprise a furanose base moiety. " Bicyclic nucleoside " (" BNA ") is a nucleoside with a bicyclic sugar. In certain embodiments, bicyclic sugar comprises a bridge between 4 ' and 2 ' furanose ring atoms. In certain embodiments, bicyclic sugar comprises a bridge between 5 ' and 3 ' furanose ring atoms. In some such embodiments, the furanose ring is a ribose ring. In certain embodiments, the 4' to 2' bridging substituents include, but are not limited to, 4'-CH2-2', 4'-(CH2)2-2', 4'-(CH2)3-2', 4'-CH2-O-2' ("LNA"), 4'-CH2-S-2', 4'-(CH2)2-O-2' ("ENA"), 4'-CH(CH3)-O-2' ("constrained ethyl" or "cEt" when in the S configuration), 4'-CH2-O-CH2-2', 4'-CH2-N(R)-2', 4'-CH(CH2OCH3)-O-2' ( "constrained MOE" or "cMOE") and its analogs (e.g., U.S. Patent No. 7,399,845), 4'-C(CH3)(CH3)-O-2' and its analogs (e.g., U.S. Patent No. 8,278,283), 4'-CH2-N(OCH3)-2' and its analogs (e.g., U.S. Patent No. 8,278,425), 4'-CH2-ON(CH3)-2' (e.g., U.S. Patent Publication No. 2004 / 0171570), 4'-CH2-N(R)-O-2', wherein R is H, C1-C 12 Alkyl or protecting group (e.g., U.S. Patent No. 7,427,672), 4'-CH2-C(H)(CH3)-2' (e.g., Chattopadhyaya el a1., J. Org. Chem., 2009, 74, 118-134 and 4'-CH2-C(=CH2)-2' and the like (e.g., U.S. Patent No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated by reference. Additional representative U.S. patents and U.S. patent publications that teach the preparation of bicyclic nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008 / 0039618; and US 2009 / 0012281, US 2013 / 0190383; and WO 2013 / 036868, The entire contents of each of them are hereby incorporated by reference. Any of the aforementioned bicyclic nucleosides with one or more stereochemical sugar configurations can be prepared, including for example α-L-ribofuranose and β-D-ribofuranose (see for example WO 99 / 14226). Unless otherwise indicated, the bicyclic nucleosides specified herein are β-D configurations. In certain embodiments, the modified sugar is a sugar substitute. In certain embodiments, the sugar substitute has an oxygen atom, for example, replaced by a sulfur, carbon or nitrogen atom. In certain such embodiments, the sugar substitute may also include bridging and / or non-bridging substituents as described herein. In certain embodiments, the sugar substitute includes a ring having other than 5 atoms. In certain such embodiments, the sugar substitute includes a cyclobutyl moiety replacing a pentofuranosyl sugar. In certain embodiments, the sugar substitute includes a six-membered ring replacing a pentofuranosyl sugar. In certain embodiments, the sugar substitute includes a tetrahydropyran ("THP") replacing a pentofuranosyl sugar. In certain embodiments, the sugar substitute includes a morpholino replacing a pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to U.S. Patent Nos. 4,981,957; 5,118,800; 5,166,315; 5,185,444; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5, and 9,005,906, The entire contents of each of the foregoing are hereby incorporated herein by reference. In some embodiments, the sugar surrogate comprises an acyclic moiety. In certain embodiments, the sugar surrogate is an unlocked nucleic acid ("UNA (unlocked nucleic acid)"). UNA is an unlocked acyclic nucleic acid in which any bond of the sugar has been removed to form an unlocked "sugar" residue. In one example, UNA also encompasses monomers in which the bond between C1' and C4' (i.e., the covalent carbon-oxygen-carbon bond between the C1' and C4' carbons) has been removed. In another example, the C2'-C3' bond of the sugar (i.e., the covalent carbon-carbon bond between the C2' and C3' carbons) has been removed. Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Patent No. 8,314,227; and U.S. Patent Publication Nos. 2013 / 0096289, 2013 / 0011922, and 2011 / 0313020, the entire contents of each of which are hereby incorporated herein by reference. In certain embodiments, sugar substitutes include peptide nucleic acids ("PNA (peptide nucleic acid)"), acyclic butyl nucleic acids (see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., US2013 / 130378, the entire contents of which are hereby incorporated by reference herein. Many other bicyclic and tricyclic sugars and sugar substitute ring systems known in the art can be used for modified nucleosides. In certain aspects, the disclosure relates to compounds comprising at least one oligonucleotide, wherein the nucleosides of such oligonucleotides comprise one or more types of modified sugars and / or unmodified sugars arranged in a defined pattern or "sugar motif" along the oligonucleotide or a region thereof. In some cases, such sugar motifs include, but are not limited to, any sugar modification pattern described herein. In certain embodiments, oligonucleotides include spaced polymer sugar motifs. Spaced polymer oligonucleotides include or consist of the following: regions with two external "wing" regions and central or internal "spacer" regions. Spacer and wing regions form a continuous sequence of nucleosides, wherein most of the nucleosides sugars of each wing are different from most of the nucleosides sugars of the interval. In certain embodiments, the wing region includes most of modified sugars, and the interval includes most of unmodified sugars. In certain embodiments, the nucleosides of the interval are deoxynucleosides. Compounds with spaced polymer sugar motifs are described in, for example, U.S. Patent No. 8,790,919, the entire contents of which are incorporated herein by reference. In certain embodiments, one or two oligonucleotides of the double-stranded compound include a triplet sugar motif. An oligonucleotide with a triplet sugar motif includes three identical sugar modifications on three consecutive nucleosides. In certain embodiments, the triplet is at or near the cleavage site of the oligonucleotide. In certain embodiments, the oligonucleotide of the double-stranded compound may include more than one triplet sugar motif. In certain embodiments, the identical sugar modification of the triplet sugar motif is a 2'-F modification. For example, compounds with triplet sugar motifs are disclosed in U.S. Patent No. 10,668,170, the entire contents of which are incorporated herein by reference. In certain embodiments, one or two oligonucleotides of the double-stranded compound include a quadruplex sugar motif. Oligonucleotides with a quadruplex sugar motif include four identical sugar modifications on four consecutive nucleosides. In certain embodiments, the quadruplex is at or near the cleavage site. In certain embodiments, the oligonucleotides of the double-stranded compound may include more than one quadruplex sugar motif. In certain embodiments, the identical sugar modification of the quadruplex sugar motif is a 2'-F modification. For double-stranded compounds with a duplex region of 19 to 23 nucleotides in length, the cleavage site of the antisense oligonucleotide is generally at about the 10th, 11th and 12th positions from the 5' end. In certain embodiments, counting from the first nucleoside at the 5' terminus of the sense oligonucleotide, or counting from the first paired nucleotide in the duplex region at the 5' terminus of the sense oligonucleotide, the quadruplex sugar motif is at position 8, 9, 10, 11; position 9, 10, 11, 12; position 10, 11, 12, 13; position 11, 12, 13, 14; or position 12, 13, 14, 15 of the sense oligonucleotide. In certain embodiments, counting from the first nucleoside at the 5' terminus of the antisense oligonucleotide, or counting from the first paired nucleotide in the duplex region at the 5' terminus of the antisense oligonucleotide, the quadruplex sugar motif is at position 8, 9, 10, 11; position 9, 10, 11, 12; position 10, 11, 12, 13; position 11, 12, 13, 14; or position 12, 13, 14, 15 of the antisense oligonucleotide. The cleavage site may vary depending on the length of the duplex region of the double-stranded compound and may alter the position of the quadruplex accordingly. In certain embodiments, the oligonucleotide comprises an alternating sugar motif. In certain embodiments, one or both oligonucleotides of the double-stranded compound comprise an alternating sugar motif. An oligonucleotide having an alternating sugar motif comprises at least two different sugar modifications, wherein one or more consecutive nucleosides comprising a first sugar modification alternate with one or more consecutive nucleosides comprising a second sugar modification and one or more consecutive nucleosides comprising a third sugar modification, and so on. For example, if A, B, and C each represent a modification type of a nucleoside, the alternating motif can be "ABABABABABAB...," "AABBAABBAABB..." "AABAABAABAAB...," "AAABAAABAAAB...," "AAABBBAAABBB...," or "ABCABCABCABC..." etc. In certain embodiments, the alternating sugar motif is repeated for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 consecutive nucleobases along the oligonucleotide. In certain embodiments, the alternating sugar motif is composed of two different sugar modifications. In certain embodiments, the alternating sugar motif comprises 2'-OMe and 2'-F sugar modifications. In certain embodiments, each nucleoside of oligonucleotide is modified independently by one or more sugar modifications provided herein. In certain embodiments, each oligonucleotide of double-stranded compound has one or more sugar motifs provided herein independently. In certain embodiments, the oligonucleotide comprising sugar motif is modified completely, because each nucleoside except the nucleoside comprising sugar motif comprises sugar modification. Nucleobase modifications and motifs In certain embodiments, the compounds described herein comprise modified oligonucleotides. In certain embodiments, modified oligonucleotides comprise one or more nucleosides containing modified nucleobases. In certain embodiments, modified oligonucleotides comprise one or more nucleosides without nucleobases, referred to as abasic nucleosides. In certain embodiments, the modified nucleobase is selected from the group consisting of: a 5-substituted pyrimidine, a 6-azapyrimidine, an alkyl or alkynyl substituted pyrimidine, an alkyl substituted purine, and N-2, N-6, and O-6 substituted purines. In certain embodiments, the modified nucleobase is selected from the group consisting of: 2-aminopropyladenine, 5-hydroxymethylcytosine, 5-methylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl (C≡C-CH3) uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-sulfanyl, 8-hydroxy, 8-nitro ...thymine, 5-ribosyluracil (pseudo and other 8-substituted purines, 5-halogen, especially 5-bromo, 5-trifluoromethyl, 5-halouracil and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl4-N-benzoylcytosine, 5-methyl4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size expanded bases and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines such as 1,3-diazepine Oxazine-2-one, 1,3-diazaphenothiazine-2-one and 9-(2-aminoethoxy)-1,3-diazaphene Modified nucleobases may also include those in which the purine or pyrimidine base is replaced by other heterocycles (eg, 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and 2-pyridone). Other nucleobases include those disclosed below: U.S. Patent 3,687,808; Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P.ed. Wiley-VCH, 2008; The Concise Encyclopedia Of Polymer Science And Engineering, pp. 858-859; Kroschwitz, JL, Ed., John Wiley & Sons, 1990, 858-859; Englisch et al. al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, YS, Chapter 15, dsRNA Research and Applications, pages 289-302; Antisense Research and Applications, Crooke, ST and Lebleu, B., Eds., CRC Press, 1993, 273-288; Antisense Drug Technology, Crooke ST, Ed, CRC Press, 2008, 163-166 and 442-443 (Chapters 6 and 15), Each of which is hereby incorporated herein by reference. Publications that teach the preparation of some of the above-mentioned modified nucleobases, as well as other modified nucleobases, include, but are not limited to, U.S. Applications 2003 / 0158403 and 2003 / 0175906; U.S. Patents 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,434,257; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,811,534; 5,7 50,692; 5,948,903; 5,587,470; 5,457,191; 5,763,588; 5,830,653; 5,808,027; 6,005,096.6,015,886; 6,147,200; 6,166,197; 6,166,199; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, The entire contents of which are hereby incorporated herein by reference. In certain embodiments, the compounds described herein comprise oligonucleotides. In certain embodiments, oligonucleotides comprise modified and / or unmodified nucleobases arranged in a defined pattern or motif along an oligonucleotide or its region. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases is modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases in the modified oligonucleotides are 5-methylcytosine. In certain embodiments, the modified oligonucleotide comprises a block of modified nucleobases. In certain such embodiments, the block is at the 3' end of the oligonucleotide. In certain embodiments, the block is within 3 nucleosides at the 3' end of the oligonucleotide. In certain embodiments, the block is at the 5' end of the oligonucleotide. In certain embodiments, the block is within 3 nucleosides at the 5' end of the oligonucleotide. Internucleoside linkage modifications and motifs 3' to 5' phosphodiester linkages are naturally occurring internucleoside linkages in RNA and DNA. In certain embodiments, the compounds described herein have one or more modified, i.e., non-naturally occurring internucleoside linkages. Certain non-naturally occurring internucleoside linkages can impart desired properties, such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and improved stability in the presence of nucleases. Representative phosphorus-containing modified internucleoside linkages include, but are not limited to, phosphotriesters, alkylphosphonates (e.g., methylphosphonates), hypophosphites, and phosphorothioates ("P=S") and phosphorodithioates ("HS-P=S"). Representative non-phosphorus-containing internucleoside linkage groups include, but are not limited to, methylenemethylimino (-CH2-N(CH3)-O-CH2), thiodiesters, thiocarbamates (-OC(=O(NH)-S-); siloxanes (-O-SiH2-O-); and N,N'-dimethylhydrazine (-CH2-N((CH3)-N((CH3)-). Methods for preparing phosphorus-containing and non-phosphorus-containing internucleoside linkages are well known to those skilled in the art. Neutral internucleoside linkages include, but are not limited to, phosphotriesters, methylphosphonates, MMI (3'- CH2-N(CH3)-O-5'), amide-3 (3'-CH2-C(=O)-N(H)-5'), amide-4 (3'-CH2-N(H)-C(=O)-5'), methylal (3'-O-CH2-O-5'), methoxypropyl and thiomethylal (3'-S-CH2-O-5'). Other neutral internucleoside linkages include nonionic linkages containing the following: siloxane (dialkylsiloxane), carboxylate, formamide, sulfide, sulfonate and amide (see, for example: Carbohydrate Modifications in Antisense Research; YS Sanghvi and P.D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Other neutral internucleoside linkages include nonionic linkages containing mixed N, O, S and CH2 components. In certain embodiments, the compounds provided herein include at least one modified internucleoside linkage. The modified internucleoside linkage can be placed at any position of the oligonucleotide. For double-stranded compounds, the modified internucleoside linkage can be placed in a sense oligonucleotide, an antisense oligonucleotide, or both oligonucleotides of the double-stranded compound. In certain embodiments, the internucleoside linkage modification may occur on each nucleoside of the oligonucleotide. In certain embodiments, the internucleoside linkage modification may occur in an alternating pattern along the oligonucleotide. In certain embodiments, substantially each internucleoside linkage group is a phosphate internucleoside linkage (P=O). In certain embodiments, each internucleoside linkage group of the modified oligonucleotide is a phosphorothioate (P=S). In certain embodiments, each internucleoside linkage group of the modified oligonucleotide is independently selected from phosphorothioate and phosphate internucleoside linkages. In certain embodiments, the pattern of internucleoside linkage modification on each oligonucleotide of the double-stranded compound is the same. In certain embodiments, the pattern of internucleoside linkage modification on each oligonucleotide of the double-stranded compound is different. In certain embodiments, the double-stranded compound comprises 6 to 8 modified internucleoside linkages. In certain embodiments, 6 to 8 modified internucleoside linkages are phosphorothioate internucleoside linkages or alkylphosphonate internucleoside linkages. In certain embodiments, the sense oligonucleotide comprises at least two modified internucleoside linkages at one or both of the 5' and 3' ends. In certain such embodiments, the modified internucleoside linkages are phosphorothioate internucleoside linkages or alkylphosphonate internucleoside linkages. In certain embodiments, the antisense oligonucleotide comprises at least two modified internucleoside linkages at one or both of the 5' and 3' ends. In certain such embodiments, the modified internucleoside linkages are phosphorothioate internucleoside linkages or alkylphosphonate internucleoside linkages. In certain embodiments, the double-stranded compound includes an overhang region. In certain embodiments, the double-stranded compound includes a phosphorothioate or alkylphosphonate internucleoside linkage modification in the overhang region. In certain embodiments, the double-stranded compound includes a phosphorothioate or alkylphosphonate internucleoside linkage, and the linkage connects the overhang nucleotide and the paired nucleotide adjacent to the overhang nucleotide. For example, at least two phosphorothioate internucleoside linkages may be present between the three nucleosides at the end, two of which are overhang nucleosides, and the third is a paired nucleoside adjacent to the overhang nucleoside. These three nucleosides at the end may be at the 3' end of the antisense oligonucleotide, the 3' end of the sense oligonucleotide, the 5' end of the antisense oligonucleotide, or the 5' end of the antisense oligonucleotide. In certain embodiments, the modified oligonucleotide comprises one or more internucleoside linkages with a chiral center. Representative chiral internucleoside linkages include, but are not limited to, alkylphosphonates and phosphorothioates. The modified oligonucleotide comprising an internucleoside linkage with a chiral center can be prepared as a modified oligonucleotide group comprising a stereo-irregular internucleoside linkage, or as a modified oligonucleotide group comprising a phosphorothioate linkage in a specific stereochemical configuration. In certain embodiments, the modified oligonucleotide group comprises a phosphorothioate internucleoside linkage, wherein all phosphorothioate internucleoside linkages are stereo-irregular. Such modified oligonucleotides can be produced using a synthetic method, which results in the random selection of the stereochemical configuration of each phosphorothioate linkage. As known to those skilled in the art, each single phosphorothioate in each single oligonucleotide molecule has a limited stereochemical configuration. In certain embodiments, the modified oligonucleotide group is enriched in a specific, independently selected stereochemical configuration comprising one or more modified oligonucleotides of a specific phosphorothioate internucleoside linkage. In certain embodiments, the specific configuration of a specific phosphorothioate linkage is present in at least 65% of the molecules in the group. In certain embodiments, the specific configuration of a specific phosphorothioate linkage is present in at least 70% of the molecules in the group. In certain embodiments, the specific configuration of a specific phosphorothioate linkage is present in at least 80% of the molecules in the group. In certain embodiments, the specific configuration of a specific phosphorothioate linkage is present in at least 90% of the molecules in the group. In certain embodiments, the specific configuration of a specific phosphorothioate linkage is present in at least 99% of the molecules in the group. Such enriched modified oligonucleotide groups can be produced using synthetic methods known in the art, for example, Oka et al., JACS 125, 8307 (2003), Wan et al. Nuc. Acid. Res. 42, 13456 (2014) and the method described in WO 2017 / 015555. In certain embodiments, the modified oligonucleotide group is enriched in a modified oligonucleotide having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, the population of modified oligonucleotides is enriched for modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration. Conjugated Group In certain embodiments, the compounds described herein comprise or consist of one or more oligonucleotides and optionally one or more conjugated groups. The conjugated groups may be connected to one or both ends of the oligonucleotide and / or at any internal position. In certain embodiments, the conjugated groups are connected to the 3' ends of the oligonucleotide. In certain embodiments, the conjugated groups are connected to the 5' ends of the oligonucleotide. In certain embodiments, the oligonucleotide is covalently linked to one or more conjugated groups. In certain embodiments, the conjugated group is an end group connected to one or both ends of an oligonucleotide. In certain such embodiments, the end group is connected to the 3' end of an oligonucleotide. In certain such embodiments, the end group is connected to the 5' end of an oligonucleotide. In certain embodiments, the end group includes but is not limited to a capping group, a phosphate moiety, a protecting group, a modified or unmodified nucleoside, and two or more independently modified or unmodified nucleosides, such as an overhang. In certain embodiments, the conjugated group modifies one or more properties of the connected oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, activity, half-life, binding, absorption, tissue distribution, cell distribution, cellular uptake, charge and removal. In certain embodiments, the conjugated group enhances the affinity of the compound to the selected target, such as a molecule, cell or cell type, compartment (e.g., cell or organ compartment), tissue, organ or body region, compared to a compound without such a conjugated group. In certain embodiments, the conjugated group imparts new properties to the connected oligonucleotide, for example, enabling detection of a fluorophore or reporter group of an oligonucleotide. In certain embodiments, conjugate groups include, but are not limited to, intercalators, reporters, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterol, bile acid moieties, folic acid, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluorescein, rhodamine, coumarin, fluorophores, and dyes. In certain embodiments, the conjugate group includes an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, benzothiadiazide, chlorothiazide, diazepam, (diazepine), indo-methicin, barbiturates, cephalosporins, sulfonamides, antidiabetic agents, antibacterial agents, or antibiotics. In certain embodiments, the conjugated group is a targeting moiety. In certain embodiments, the targeting moiety includes, but is not limited to, a lectin, a glycoprotein, a lipid, a protein, a peptide, a peptide mimetic, a receptor ligand, an antibody, a thyrotropin, a melanocyte stimulating hormone, a surfactant protein A, a carbohydrate, a carbohydrate derivative, a modified carbohydrate, a carbohydrate cluster, a polysaccharide, a modified polysaccharide or a polysaccharide derivative, a mucin carbohydrate, a multivalent lactose, a multivalent galactose, N-acetyl-galactosamine (GalNAc), N-acetylglucosamine multivalent mannose, multivalent fucose, a glycosylated polyamino acid, a multivalent galactose, transferrin, a bisphosphonate, polyglutamic acid, polyaspartic acid, a lipid, cholesterol, a steroid, a bile acid, folic acid, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic. In certain embodiments, the conjugate groups may include, but are not limited to, the conjugate groups described in the following references: for example, cholesterol (e.g., Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86:6553-6556); cholic acid (e.g., Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060); thioethers, for example, hexyl-S-tritylthiol (e.g., Manoharan et al., Ann. NY. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770); thiocholesterol (e.g., Oberhauser et al., Nucl. Acids Res., 1992, 20: 533-538); aliphatic chains, for example, dodecanediol or undecyl residues (e.g., Saison-Behmoaras et al., EMBOJ, 1991, 10: 1111-1118; Kabanov et al., FEBS Lett., 1990, 259: 327-330; Svinarchuk et al., Biochimie, 1993, 75: 49-54); phospholipids, for example, di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycerol-3-H-phosphate (e.g., Manoharan et al., Tetrahedron Lett., 1995, 36: 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18: 3777-3783); polyamine or polyethylene glycol chain (e.g., Manoharan et al., Nucleosides & Nucleotides, 1995, 14: 969-973); adamantaneacetic acid (e.g., Manoharan et al., Tetrahedron Lett., 1995, 36: 3651-3654); palmityl (e.g., Mishra et al., Biochim. Biophys. Acta, 1995, 1264: 229-237); octadecylamine or hexylamino-carbonyloxycholesterol moiety (e.g., Crooke et al. J. Pharmacol. Exp. Ther., 1996, 277: 923-937); tocopherol (e.g., Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220 and Nishina et al., Molecular Therapy, 2008, 16: 734-740); GalNAc and other carbohydrates (e.g., Maier et al., Bioconjugate Chemistry, 2003, 14, 18-29; Rensen et al., J. Med. Chem. 2004, 47, 5798-5808; WO 2009 / 073809 and U.S. Patents 8,106,022, 8,450,467 and 8,828,957; and WO 2014 / 179445; WO 2014 / 179620 and U.S. Patents 9,127,276, 9,181,549 and 10,844,379), each of which is incorporated herein by reference in its entirety. . The conjugated group can be connected to the oligonucleotide through a conjugated linker. In certain embodiments, the conjugated linker comprises a chain structure (e.g., a hydrocarbon chain) or an oligomer of a repeating unit or a combination of such repeating units. In certain embodiments, the conjugated linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino groups. In certain embodiments, the conjugated linker comprises at least one phosphorus group. In certain embodiments, the conjugated linker comprises at least one phosphate group. In certain embodiments, the conjugated linker comprises at least one neutral linking group. In certain embodiments, the conjugated linker includes but is not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugated linkers include but are not limited to substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C2-C 10 alkenyl or substituted or unsubstituted C2-C 10Alkynyl, wherein the non-limiting list of preferred substituents includes hydroxyl, amino, alkoxy, carboxyl, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl. In certain embodiments, the conjugated joint comprises 1 to 10 joints-nucleosides. In certain embodiments, such joints-nucleosides can be modified or unmodified nucleosides. It is generally expected that the joint-nucleosides will be cut from the compound after the compound reaches the target tissue. Therefore, the joint-nucleosides herein can be connected to each other and connected to the remainder of the compound by a cleavable bond. In this article, joint-nucleosides are not considered to be a part of oligonucleotides. Therefore, in the embodiment in which the compound comprises the oligonucleotides composed of the connection nucleosides of a specific number or range and / or have a specific complementarity percentage with the reference nucleic acid, and the compound also comprises the conjugated joint containing the conjugated joint containing joint-nucleosides, these joints-nucleosides are not counted in the length of the oligonucleotide and are not used to determine the complementarity percentage of the oligonucleotide for the reference nucleic acid. In certain embodiments, conjugated groups and conjugated linkers and other modifications include, but are not limited to, those described in the following references: US 5,994,517; US 6,300,319; US 6,660,720; US 6,906,182; US 7,262,177; US 7,491,805; US 8,106,022; US 7,723,509; US 9,127,276; US 2006 / 0148740; US 2011 / 0123520; WO2013 / 033230;W02012 / 037254,Biessen et al.,J.Med.Chem.1995,38,1846-1852;Lee et al.,Bioorganic&Medicinal Chemistry 2011,19,2494-2500;Rensen etal.,J.Biol.Chem.2001,276,37577-37584;Rensen et al.,J.Med.Chem.2004,47,5798-5808;Sliedregt et al.,J.Med.Chem.1999,42,609-618;Valentijn et al.,Tetrahedron,1997,53,759-770;Lee,Carhohydr Res,1978,67,509-514;Connolly etal.,J Biol Chem,1982,257,939-945;Pavia et al.,Int J Pep Protein Res,1983,22,539-548;Lee et al.,Biochem,1984,23,4255-4261;Lee et al.,Glycoconjugate J,1987,4,317-328;Toyokuni et al.,Tetrahedron Lett,1990,31,2673-2676;Biessen et al.,J Med Chem,1995,38,1538-1546,Valentijn et al.,Tetrahedron,1997,53,759-770;Kim et al.,Tetrahedron Lett,1997,38,3487-3490;Lee et al.,Bioconjug Chem,1997,8,762-765,Kato et al.,Glycohiol,2001,11,821-829;Rensen et al.,J BiolChem,2001,276,37577-37584;Lee et al.,Methods Enzymol,2003,362,38-43,Westerlind et al,Glycoconj J,2004,21,227-241,Lee et al,Bioorg Med ChemLett,2006,16(19),5132-5135;Maierhofer et al.,Bioorg Med Chem,2007,15,7661-7676;Khorev et al.,Bioorg Med Chem,2008,16,5216-5231;Lee et al.,Bioorg MedChem,2011,19,2494-2500;Komilova et al.,Analyt Biochem,2012,425,43-46;Pujol etal.,Angew Chemie Int Ed Engl,2012,51,7445-7448;Biessen et a1.,J Med Chem,1995,38,1846-1852;Sliedregt et al.,J Med Chem,1999,429-668;Rensen et al. al.,JMed Chem,2004,47,5798-5808;Rensen et al.,Arterioscler Thromh Vase Biol,2006,26,169-175;van Rossenberg et al.,Gene Ther,2004,11,457-464;Sato et al.,JAmChem Soc,2004,126,14013-14022;Lee et al.,J Org Chem,2012,757-7571; al.,FASEB J,2000,14,1784-1792;Rajur et al.,Bioconjug Chem,1997,8,935-940;Duffet al.,Methods Enzymol,2000,313,297-321;Maier et a1.,Bioconjug Chem,2003,14,18-29;Jayaprakash et a1,Org Lett,2010,12,5410-5413;Manoharan,AntisenseNucleic Acid Drug Dev,2002,12,103-128;Merwin et al,Bioconjug Chem,1994,206-2016; et al.,Bioorg Med Chem,2013,21,5275-5281;. International applications WO1998 / 013381; WO2011 / 038356; WO1997 / 046098; WO2008 / 098788; WO2004 / 101619; WO2012 / 037254; WO2011 / 120053; WO2011 / 100131; WO2011 / 163121; WO2012 / 177947; WO2013 / 033230; WO2013 / 075035; WO2012 / 0831 85; WO2012 / 083046; W02009 / 082607; WO2009 / 134487; W02010 / 144740; W02010 / 148013; WO1997 / 020563; WO201 0 / 088537; WO2002 / 043771; WO2010 / 129709; WO2012 / 068187; WO2009 / 126933; WO2004 / 024757; WO2010 / 054406 ; WO2012 / 089352; WO2012 / 089602; WO2013 / 166121; WO2013 / 165816; U.S. Patents 4,751,219; 7,582,744; 8,552,163; 8,137,695; 6,908,903; 6,383,812; 7,262,177; 6,525,031; 5,994,517; 6,660,720; 6,300,319; 7,723,509; 8, 106,022; 7,491,805; 7,491,805; 8,541,548; 8,344,125; 8,313,772; 8,349,308; 8,450,467; 8,501,930; 8,158,601; 7,262,177; 6,906,182; 6,620,916; 8,435,491; 8,404,862; 7,851,615; published U.S. patent application publication US2011 / 0097264; US2011 / 0097265; US2013 / 0004427; US2003 / 0119724; US2011 / 0207799; US2012 / 0035115; US2012 / 0230938; US2005 / 0164235; US2006 / 0183886; US2012 / 0136042; US2012 / 0095075; US2013 / 0109817; US2006 / 0148740; US2008 / 0206869; US2012 / 0165393; US2012 / 0101148; US2013 / 0121954; US2011 / 0123520; US2003 / 0077829; US2008 / 0108801; and US2009 / 0203132; Each of which is incorporated herein by reference in its entirety. Certain targeting moieties In certain embodiments, the compounds provided herein include a conjugated group. In certain embodiments, the oligonucleotides provided herein include a conjugated group. In certain embodiments, the conjugated group is a targeting moiety. In certain embodiments, the targeting moiety includes one or more GalNAc. In certain embodiments, one or more GalNAc is connected to one or more positions on a furanose ring. In certain embodiments, one or more GalNAc is connected to the 2' or 3' position on the furanose ring. In certain embodiments, the furanose ring is a subunit of an oligonucleotide. In certain embodiments, the furanose ring is the 5' nucleoside sugar of an oligonucleotide. In certain embodiments, the furanose ring is the 5' nucleoside sugar of a sense oligonucleotide. In certain embodiments, the compound or oligonucleotide includes one or more subunits having the following formula or a salt, solvate or hydrate thereof: in: R 1 is H, adenine, guanine, thymine, cytosine, uracil, a carbocyclyl, a heterocyclyl, an aryl, a heteroaryl, or a nucleobase isostere; R 2 is the oligonucleotide sequence; L 1 is alkyl or alkyl-C(═O)—NH-alkyl; L 2 is alkyl or alkyl-C(═O)—NH-alkyl; L 3 is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a transamide, a carbamate, a carbonate, a urea, O, S, S(=O), S(=O)2, NH, a substituted N group, an alkyl, an alkenyl, a diene group, an alkynyl, a heteroalkyl, a phosphate; R 3 is H, -C=(O)-NH-(CH2CH2O) j -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 4is H, -C=(O)-NH-(CH2CH2O) k -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 5 is -C=(O)-NH-(CH2CH2O) m -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 6 is -C=(O)-NH-(CH2CH2O) n -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; W and Q are each independently O, NH, CH2 or CH2O; S 1 and S 2 Each independently is C(R 7 ) or N, where R 7 Each instance of is independently H, alkyl, heteroalkyl, or halogen; j is an integer from 1 to 10, inclusive; k is an integer from 1 to 10, inclusive; m is an integer from 1 to 10, inclusive; and n is an integer from 1 to 10, inclusive. In certain embodiments, R 3 , R 4 , R 5 and R 6 In certain embodiments, R 3 , R 5 and R 6 In certain embodiments, R 3 or R 4 It's H. In certain embodiments, L 1 and L 2 are the same. In certain embodiments, L 1 and L 2 are each independently an alkyl group; R 3 is H, -C=(O)-NH-(CH2CH2O) j -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 4 is H, -C=(O)-NH-(CH2CH2O) k-GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 5 is -C=(O)-NH-(CH2CH2O) m -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R 6 is -C=(O)-NH-(CH2CH2O) n -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc. In certain embodiments, L 1 and L 2 are each independently alkyl-C(═O)-NH-alkyl; R 3 is H, -C=(O)-NH-(CH2CH2O) j -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 4 is H, -C=(O)-NH-(CH2CH2O) k -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 5 is -C=(O)-NH-(CH2CH2O) m -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R 6 is -C=(O)-NH-(CH2CH2O) n -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc. In certain embodiments, R 4 It's H. In certain embodiments, L 1 and L 2 are each independently an alkyl group; R 3 is -C=(O)-NH-(CH2CH2O) j -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 4 It is H; R 5 is -C=(O)-NH-(CH2CH2O) m -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R 6 is -C=(O)-NH-(CH2CH2O) n-GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc. In certain embodiments, L 1 and L 2 are each independently alkyl-C(═O)-NH-alkyl; R 3 is -C=(O)-NH-(CH2CH2O) j -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 4 It is H; R 5 is -C=(O)-NH-(CH2CH2O) m -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R 6 is -C=(O)-NH-(CH2CH2O) n -GalNAc or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc. In certain embodiments, R 3 is -C=(O)-NH-(CH2CH2O) j -GalNAc; R 4 It is H; R 5 is -C=(O)-NH-(CH2CH2O) m -GalNAc; and R 6 is -C=(O)-NH-(CH2CH2O) n -GalNAc. In certain embodiments, R 3 is -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R 4 It is H; R 5 is -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R 6 It is -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc. In certain embodiments, the compound or oligonucleotide comprises one or more subunits having the following formula or a salt, solvate or hydrate thereof: in: R 9is H, adenine, guanine, thymine, cytosine or uracil, or is adenine, guanine, thymine, cytosine or uracil, each of which comprises a protecting group (PG), a modified nucleobase, an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl, an optionally substituted heterocyclyl or a nucleobase isostere; L is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a transamide, a carbamate, a carbonate, a urea, an alkyl group, or a heteroalkyl group; R 2 is the oligonucleotide sequence; Y1 is O, CH2, CH2O or optionally substituted NH; Y2 is O, CH2, CH2O or optionally substituted NH; Y3 is CO, SO2, P(O)O, CH2-OC(O), CH2-NH-C(O), CH2-NH-SO2 or CH2; Y4 is CO, SO2, P(O)O, CH2-OC(O), CH2-NH-C(O), CH2-NH-SO2 or CH2; n2 is 0, 1, 2, 3, 4, 5 or 6; and n1, n3, n4 and n5 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In certain embodiments, the compound or oligonucleotide comprises one or more subunits having the following formula or a salt, solvate or hydrate thereof: in: Each n is independently 1, 2, 3, 4 or 5; Each m is independently 0, 1, 2, 3, 4, 5 or 6; Each o is independently 0, 1, 2, 3, 4, 5 or 6; L1, L2 and L3 are each independently absent, C(═O) or C(═O)NH; Each Y1 is independently O, CH(R a ), S, S(=O), S(=O)2, NH, substituted N group, NHC(=O), C(=O)NH, P(=O)2-O-, P(=O)(=S)-O, P(=S)2- O, -OP(=O)2-O-, -OP(=O)(=S)-O-, -OP(=S)2-O-, -OP(=O)2-, -OP(=O)(=S)-, -OP(=S)2-; Each Y2 is independently O, CH(R b), S, S(=O), S(=O)2, NH, substituted N group, NHC(=O), C(=O)NH, P(=O)2-O-, P(=O)(=S)-O, P(=S)2- O, -OP(=O)2-O-, -OP(=O)(=S)-O-, -OP(=S)2-O-, -OP(=O)2-, -OP(=O)(=S)-, -OP(=S)2-; Het1, Het2 and Het3 are each independently an optionally substituted heteroaryl or an optionally substituted heterocyclyl; R 1 are oligonucleotide sequences joined by a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a reverse amide, a carbamate, a carbonate, a urea, an alkyl or a heteroalkyl; R5, R6 and R7 are each independently R9 is an optionally substituted heterocyclyl; Each R a are independently H, alkyl, halogen, OR c or SR c ; Each R b are independently H, alkyl, halogen, OR c or SR c ;and Each R c is independently H or alkyl. In certain embodiments, the subunit is selected from Formula I to VIII or a salt, solvate or hydrate thereof, wherein R is a modified oligonucleotide other than a 5' nucleoside. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is S. Target nucleic acid and target region In certain embodiments, the compound described herein comprises an oligonucleotide or is composed of an oligonucleotide, and the oligonucleotide comprises a region complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain embodiments, the target nucleic acid is non-coding. In certain such embodiments, the target nucleic acid is selected from mRNA and pre-mRNA, including intronic regions, exonic regions, and untranslated regions. In certain embodiments, the target RNA is mRNA. In certain embodiments, the target nucleic acid is pre-mRNA. In certain such embodiments, the target region is completely within exons. In certain such embodiments, the target region is completely within introns. In certain embodiments, the target region spans intron / exon connections. In certain embodiments, at least 50% of the target region is within introns. In certain embodiments, the compounds disclosed herein hybridize with PKK nucleic acids. The most common hybridization mechanism involves hydrogen bonds between complementary core bases of nucleic acid molecules. Hybridization can occur under different conditions. Hybridization conditions are sequence dependent and are determined by the properties and composition of the nucleic acid molecules to be hybridized. Methods for determining whether a sequence specifically hybridizes with a target nucleic acid are well known in the art. In certain embodiments, the compounds provided herein specifically hybridize with PKK nucleic acids. The nucleotide sequence encoding PKK includes but is not limited to the following: GENBANK Accession No. NM_000892 .5 (incorporated herein as SEQ ID NO: 1), NG_012095.2 truncated from 23529..54493 (incorporated herein as SEQ ID NO: 2), XM_017008181.1 (incorporated herein as SEQ ID NO: 3), NC_000004.12 truncated from 186215714 to 186258477 (incorporated herein as SEQ ID NO: 4), NM_0013183942 (incorporated herein as SEQ ID NO: 5) and NM_001318396.2 (incorporated herein as SEQ ID NO: 6). Complementarity Oligonucleotide provided herein can have the complementary percentage ratio of qualification with specific nucleic acid, target region, oligonucleotide or its part.Non-complementary core base is permissible, and prerequisite is that oligonucleotide keeps can with nucleic acid, oligonucleotide or its part specific hybridization.In certain embodiments, oligonucleotide provided herein or its specific part and target nucleic acid, target region, oligonucleotide or its specific part at least or up to 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementarity.In certain embodiments, oligonucleotide provided herein or its specific part and target nucleic acid, target region, oligonucleotide or its specific part have 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, 95% to 100% or any numerical value complementarity between these scopes. The complementarity percentage of oligonucleotide and target nucleic acid, target region, oligonucleotide or its specific part can be determined using conventional methods.For example, wherein 18 of the 20 core bases of oligonucleotide are complementary to the target region and therefore the oligonucleotide of specific hybridization will represent 90% complementarity.In this example, the remaining non-complementary core base can be clustered or interspersed with complementary core base, and it is not necessary to be connected to each other or to be connected to complementary core base.Therefore, the oligonucleotide of 18 core bases in length has four non-complementary core bases, and its flank is two regions that are fully complementary to the target nucleic acid, and the total complementarity with the target nucleic acid is 77.8%.BLAST programs known in the art (basic local alignment search tool (basic local alignment search tool)) can be used to routinely determine the complementarity percentage of the region of oligonucleotide and target nucleic acid, target region, oligonucleotide or its specific part.In certain embodiments, oligonucleotide described herein or its specific part are fully complementary to target nucleic acid, target region, oligonucleotide or its specific part (i.e. 100% complementary).For example, oligonucleotide can be fully complementary to target nucleic acid, target region, oligonucleotide or its specific part. As used herein, "complete complementarity" means that each core base of an oligonucleotide is complementary to the corresponding core base of a target nucleic acid, a target region, an oligonucleotide or a specific portion thereof. For example, a 20 core base oligonucleotide is completely complementary to a target sequence of 400 core bases, as long as there are corresponding 20 core base portions in the target nucleic acid that are completely complementary to the compound. "Complete complementarity" can also be used to refer to a specific portion of the first and / or second nucleic acid. For example, 20 core base portions in a 30 core base oligonucleotide can be "completely complementary" to 20 core base regions in a target sequence of 400 core bases. If the target sequence has a corresponding 20 core base portions in which each core base is partially complementary to the 20 core base portions in the compound, the 20 core base portions in the 30 core base compound are completely complementary to the target sequence.At the same time, the entire 30 nucleobase compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the compound are also complementary to the target sequence. In certain embodiments, oligonucleotides described herein comprise one or more mispaired core bases relative to target nucleic acid, target region, oligonucleotide or its specific part. In certain embodiments, oligonucleotides of length as described herein or as many as 12,13,14,15,16,17,18,19,20,21,22 or 23 core bases comprise no more than 4, no more than 3, no more than 2 or no more than 1 non-complementary core base relative to target nucleic acid or its specific part. In certain embodiments, oligonucleotides of length as described herein or as many as 14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29 or 30 core bases comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2 or no more than 1 non-complementary core base relative to target nucleic acid, target region, oligonucleotide or its specific part. In certain embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 at the 5' end of the oligonucleotide. In certain embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, 13 or 14 at the 3' end of the oligonucleotide. In certain embodiments, the mismatch forms a wobble base pair with the corresponding nucleobase on the target nucleic acid. For example, in certain embodiments, the mismatch forms a wobble base pair selected from the following: hypoxanthine (nucleobase of inosine) and uracil (I:U base pair); guanine and uracil (G:U base pair); hypoxanthine and adenine (I:A base pair); and hypoxanthine and cytosine (I:C base pair). Therefore, in certain embodiments, the nucleobase of the mismatch on the oligonucleotide comprises hypoxanthine, guanine or uracil. In certain embodiments, the oligonucleotides described herein can be complementary to portions of nucleic acids. "Portion" as used herein refers to a limited number of continuous nucleobases in a nucleic acid region. "Portion" can also refer to a limited number of continuous nucleobases of an oligonucleotide. In certain embodiments, at least 8 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 9 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 10 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 11 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 12 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 13 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 14 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 15 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. In certain embodiments, at least 16 nucleobase portions in an oligonucleotide and a nucleic acid are complementary. It is also contemplated that oligonucleotides are complementary to at least 9, 10, 17, 18, 19, 20, 21, 22, 23 or more core base portions in nucleic acid or to the range limited by any two of these values. In certain embodiments, oligonucleotides are antisense oligonucleotides. In certain embodiments, the part of antisense oligonucleotides is compared with the isometric portion of target nucleic acid. In certain embodiments, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 core base portions are compared with the isometric portion of target nucleic acid. In certain embodiments, oligonucleotides are sense oligonucleotides. In certain embodiments, the part of sense oligonucleotides is compared with the isometric portion of antisense oligonucleotides. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion of a sense oligonucleotide is compared to an equal length portion of an antisense oligonucleotide. Identity Oligonucleotides provided herein can also have a limited percentage identity with specific nucleic acids, target regions, oligonucleotides or their specific parts. Used herein, if the oligonucleotide has the same nuclear base pairing ability, it is identical to the sequence disclosed herein. For example, a DNA containing a thymidine replacing the uracil in the disclosed RNA sequence will be considered identical to the RNA sequence, because both uracil and thymidine are paired with adenine. Shortening and extension forms of compounds described herein and compounds with different bases relative to compounds provided herein are also considered. Different bases can be adjacent to each other or dispersed throughout the compound. The identity percentage of an oligonucleotide is calculated according to the number of bases with the same base pairing relative to the sequence compared thereto. In certain embodiments, oligonucleotides described herein or its part and nucleic acid disclosed herein, oligonucleotides or its part one or more have or have at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homogeneity.In certain embodiments, oligonucleotides described herein and specific nucleic acid or oligonucleotides or its part have about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homogeneity, or any percentage between such values. In certain embodiments, oligonucleotides may have one or more mispaired nucleobases. In certain such embodiments, mispairing is at the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th or 14th position at the 5' end of oligonucleotides. In certain such embodiments, mispairing is at the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th or 12th, 13th or 14th position at the 3' end of oligonucleotides. In certain embodiments, the part of oligonucleotides is compared with the isometric portion of target nucleic acid. In certain embodiments, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleobase parts are compared with the isometric portion of target nucleic acid. In certain embodiments, oligonucleotides are sense oligonucleotides. In certain embodiments, the part of sense oligonucleotides is compared with the isometric portion of target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of a target nucleic acid. Pharmaceutical compositions and preparations The compounds described herein can be mixed with pharmaceutically active substances or inert substances for the preparation of pharmaceutical compositions or formulations. The compositions and methods for preparing pharmaceutical compositions depend on many criteria, including but not limited to the route of administration, the extent of the disease, or the dose to be administered. Certain embodiments provide pharmaceutical compositions comprising one or more compounds or their salts. In certain embodiments, the compound is an antisense oligonucleotide. In certain embodiments, the compound is an oligomeric compound. In certain embodiments, the compound comprises one or more modified oligonucleotides or consists of one or more modified oligonucleotides. In certain such embodiments, the pharmaceutical composition comprises one or more compounds and a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, the pharmaceutical composition comprises one or more compounds and a sterile saline solution. In certain embodiments, such a pharmaceutical composition consists of a compound and a sterile saline solution. In certain embodiments, sterile saline is pharmaceutical grade saline. In certain embodiments, the pharmaceutical composition comprises one or more compounds and sterile water. In certain embodiments, the pharmaceutical composition consists of a compound and sterile water. In certain embodiments, sterile water is pharmaceutical grade water. In certain embodiments, the pharmaceutical composition comprises one or more compounds and phosphate-buffered saline (PBS). In certain embodiments, the pharmaceutical composition consists of a compound and sterile PBS. In certain embodiments, the sterile PBS is a pharmaceutical grade PBS. By combining the compound of the targeting PKK described herein with a suitable pharmaceutically acceptable diluent or carrier, the compound can be used in a pharmaceutical composition. In certain embodiments, the pharmaceutically acceptable diluent is water, such as sterile water suitable for injection. Therefore, in one embodiment, the method described herein uses a pharmaceutical composition comprising a compound of the targeting PKK and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is water. In certain embodiments, the compound comprises one or more modified oligonucleotides provided herein or is composed of one or more modified oligonucleotides provided herein. The pharmaceutical composition comprising the compound provided herein encompasses any pharmaceutically acceptable salt, ester or salt of such ester or any other oligonucleotide, which can provide (directly or indirectly) its biologically active metabolite or residue after being applied to an animal (including humans). In certain embodiments, the compound is an antisense oligonucleotide. In certain embodiments, the compound is an oligomeric compound. In certain embodiments, the compound comprises one or more modified oligonucleotides or is composed of one or more modified oligonucleotides. Therefore, for example, the disclosure also relates to a pharmaceutically acceptable salt, a prodrug, a pharmaceutically acceptable salt of such a prodrug, and other bioequivalents of the compound. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium salts and potassium salts. Prodrugs may be included in other nucleosides incorporated into one end or both ends of the compound, which are cut by endogenous nucleases in vivo to form active compounds. In certain embodiments, the compound or composition also comprises a pharmaceutically acceptable carrier or diluent. Example

[0238] The following examples describe methods for identifying lead compounds targeting PKK. Certain compounds were found to have high potency and tolerability.

[0239] The following examples are only used to illustrate the compounds described herein and are not intended to limit them. The following examples and the associated sequence table attached to this document can identify the sequence as "RNA" or "DNA"; however, as disclosed herein, these sequences can be modified with any combination of chemical modifications. It will be readily understood by those skilled in the art that in some cases, it is arbitrary to designate a sequence as "RNA" or "DNA". For example, an oligonucleotide comprising a nucleoside containing a 2'-OH sugar moiety and a thymine base can be described as a DNA with a modified sugar (2'-OH for the natural 2'-H of DNA) or an RNA with a modified base (methylated uracil for the natural uracil of RNA). Therefore, the nucleic acid sequences provided herein, including but not limited to the nucleic acid sequences in the sequence table, are intended to cover nucleic acids containing any combination of natural or modified RNA and / or DNA, including but not limited to such nucleic acids with modified nucleobases.

[0240] Each reference cited in this application is hereby incorporated by reference in its entirety.

[0241] Unless otherwise indicated in the individual compound chemical tables below, the compounds are unmodified. Abbreviations for chemical modifications are provided in Table 1 below. IA and IS in Ref ID NO: identify the antisense and sense strands of the compound, respectively. Table 1 Chemical nomenclature abbreviation structure ‘m’ 2'-O-methyl sugar modifications (e.g., mA, mG, mC, mU) ‘f’ 2'-F sugar modifications (e.g., fA, fG, fC, fU) ‘*’ Phosphorothioate internucleoside linkages ‘. Phosphate internucleoside linkages 'dQ' Inverted abasic deoxyribose ‘H1’ Formula I ‘H2’ Formula II ‘H4” Formula III ‘H6” Formula IV ‘H7’ Formula V ‘H9’ Formula VI 'Hd' Formula VII Hl Formula VIII Example 1 - Inhibition of PKK in HEK-293T cells

[0242] HEK-293T cells were seeded at 20,000 cells / well in antibiotic-free medium in a white-walled 96-well plate. The next day, cells were co-transfected with 50 ng of PKK-siCHECK-2 and 10 nM PKK compound using Lipofectamine 2000 (each transfection was performed in triplicate). The cells were then incubated at 37°C / 5% CO2 for 48 hours.

[0243] The expression of firefly and Renilla luciferase was evaluated using Dual-Luciferase Reporter 1000 Assay (Promega Cat#E1980) according to the kit instructions. The expression of firefly and Renilla luciferase was measured using a luminometer. Renilla luciferase was used as a readout of PKK gene expression, and firefly was used as an internal control. All Renilla readings from each well were normalized relative to their corresponding firefly readings to obtain Renilla: Firefly ratio. The ratio obtained by each well of the transfected compound was then further normalized relative to the ratio obtained by the cells not transfected with the compound. These non-transfected cells were used as 100% control. PKK inhibition was determined by comparing PKK expression with non-transfected cells, and was reported as PKK inhibition % (Tables 2 to 4). Table 2 Inhibition of PKK mRNA by double-stranded compounds targeting SEQ ID NO: 1 Table 3 Inhibition of PKK mRNA by double-stranded compounds targeting SEQ ID NO: 1 Table 4 Inhibition of PKK mRNA by double-stranded compounds targeting SEQ ID NO: 1 Example 2 - Dose-dependent inhibition of human PKK in HEK-293T cells

[0244] Compounds that showed significant in vitro inhibition of PKK mRNA from the above studies were selected and tested at different doses in HEK-293T cells as described above. Compounds were tested at concentrations of 0.01, 0.1, 1 and 10 nM and IC50 values ​​were calculated (Table 5). Table 5 Example 3: Effects of compounds targeting human PKK in cynomolgus monkeys

[0245] The target compound identified from in vitro gene expression screening was evaluated in cynomolgus monkeys (Table 7). Before the study, the monkeys were kept isolated and the general health of the animals was observed every day. On the first day of the study, a single 6 mg / kg subcutaneous dose of oligonucleotide was injected to each group of ten 1 cynomolgus monkeys. During the study, the monkeys were observed every day to see if there were signs of disease or pain. Animals were blooded for serum collection and analysis on days -6 and 1 (before administration), 4, 8, 15, 22, 29, 36, 43, 50, 57 and 64. The scheme was approved by the Institutional Animal Care and Use Committee (IACUC). Using an ELISA specific for human angiotensinogen (and cross-reacting with cynomolgus monkeys), circulating PKK levels were quantified according to the manufacturer's scheme (IBLAmerica#27412). PKK inhibition data were expressed as a percentage of baseline values ​​(day 1 before administration) (Table 8). Table 6 Compound sequence Table 7 Compound Chemistry Table 8 Average PKK inhibition Example 4: Effects of compounds targeting human PKK in cynomolgus monkeys

[0246] The target compounds identified from in vitro gene expression screening were evaluated in cynomolgus monkeys (Table 10). Prior to the study, the monkeys were kept in isolation and the general health of the animals was observed every day. On the first day of the study, a single 4 mg / kg subcutaneous dose of oligonucleotide was injected to each of eight groups of 2 cynomolgus monkeys. During the study, the monkeys were observed every day for signs of disease or pain. Blood was collected from the animals on days -6 and 1 (before administration), 4, 8 and 15 for serum collection and analysis. Future collection will be carried out on days 22, 29, 36, 43, 50, 57, 64, 71, 78 and 85. In the second group of experiments, blood was collected from the animals on days -6 and 1 (before administration), 4, 8, 15 and 22 for serum collection and analysis. Future collection of the second group of experiments will be carried out on days 29, 36, 43, 50, 57, 64, 71, 78 and 85. In the third group of experiments, blood was collected from animals on days -6 and 1 (before administration), 4, 8, 15, 22, 29 and 36 for serum collection and analysis. Future collections for the third group of experiments will be conducted on days 43, 50, 57, 64, 71, 78 and 85. In the fourth group of experiments, blood was collected from animals on days -6 and 1 (before administration), 4, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 and 85 for serum collection and analysis. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC). Using an ELISA specific for human angiotensinogen (and cross-reacting with cynomolgus monkeys), circulating PKK levels were quantified according to the manufacturer's protocol (IBL America #27412). PKK inhibition data are expressed as a percentage of baseline values ​​(day 1 before administration) and the mean value of the group for each compound. The results of the four experiments are shown in Tables 11, 12, 13, and 14. Clinical chemistry was performed on Day -1 or Day -6, and Day 63 or 64, and Day 92. There were no test article-related effects on body weight (Table 15), and all serum chemistry values ​​were within reference ranges (Tables 16 and 17). Table 9 Compound sequence Table 10 Compound Chemistry Table 11 Average PKK inhibition Table 12 Average PKK inhibition Table 13 Average PKK inhibition Table 14 Average PKK inhibition Table 15 Weight(kg) Compound Day -1 Day 63 Day 91 RD2423 Cynomolgus Monkey #1 2.4 2.4 2.4 RD2423 Crab-eating monkey #2 2.6 2.6 2.7 RD2436 Cynomolgus Monkey #1 2.9 3.1 3.2 RD2436 Cynomolgus Monkey #2 2.5 2.6 2.7 RD2437 Crab-eating monkey #1 3.1 3.2 3.2 RD2437 Crab-eating monkey #2 2.6 2.7 2.9 RD2438 Cynomolgus Monkey #1 3.2 3.2 3.4 RD2438 cynomolgus monkey #2 2.5 2.6 2.6 RD2439 cynomolgus monkey #1 3.6 4.1 N / A RD2439 cynomolgus monkey #2 2.7 2.8 N / A RD2440 Cynomolgus Monkey #1 3.9 4.3 N / A RD2440 Cynomolgus Monkey #2 2.3 2.4 N / A RD2442 Crab-eating monkey #1 4.4 4.5 4.6 RD2442 Crab-eating monkey #2 2.3 2.4 2.5 RD2492 cynomolgus monkey #1 4 4 N / A RD2492 Cynomolgus Monkey #2 2.3 2.3 N / A Table 16 Liver function markers Table 17 Renal function markers Example 5: Effects of compounds targeting human PKK in cynomolgus monkeys

[0247] The target compound was evaluated in cynomolgus monkeys (Table 19). Before the study, the monkeys were kept in isolation and the general health of the animals was observed every day. On the first day of the study, a single 4 mg / kg subcutaneous dose of oligonucleotide was injected to each of eight groups of 2 cynomolgus monkeys. During the study, the monkeys were observed every day to see if there were signs of disease or pain. Blood was collected from the animals on days -6 and 1 (before administration), 8, 15 and 22 for serum collection and analysis. Future collection will be carried out on days 29, 36, 43, 50, 57, 64 and 71. In the second group of experiments, blood was collected from the animals on days -6 and 1 (before administration), 8, 15, 22, 29, 36, 43, 50, 57, 64 and 71. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC). Circulating PKK levels were quantified using an ELISA specific for human angiotensinogen (and cross-reacted with cynomolgus monkeys) according to the manufacturer's protocol (IBLAmerica #27412). PKK inhibition data were expressed as a percentage of baseline values ​​(day 1 before administration) and the mean value of the group for each compound. Results from two groups of experiments are shown in Tables 20 and 21. Clinical chemistry was performed on day -1 or day -6, and day 64, and day 92. There was no effect on body weight associated with the test article (Table 22), and all serum chemistry values ​​were within the reference range (Tables 23 and 24). Table 18 Compound sequence Table 19 Compound Chemistry Table 20 Average PKK inhibition Table 21 Average PKK inhibition Table 22 Weight(kg) Compound Day -1 Day 64 Day 92 RD2424 Cynomolgus Monkey #1 3.1 3.1 3.1 RI)2424 Crab-eating monkey #2 3.2 3.6 3.7 RD2425 Cynomolgus Monkey #1 2.9 3.3 N / A RI)2425 Crab-eating monkey #2 3.1 3.5 N / A RD2426 Cynomolgus Monkey #1 3.5 3.9 N / A RD2426 Crab-eating monkey #2 2.8 3.2 N / A Table 23 Liver function markers Table 24 Renal function markers Example 6: Effects of compounds targeting human PKK in Lewis rats

[0248] On day 1, groups 1 to 3 of female Lewis rats (5 females / group, 8 weeks old) were given a single subcutaneous (SC) injection of 0 (vehicle control (phosphate buffered saline (PBS)), 200 mg / kg RD2423 or 200 mg / kg RD2438 at a dose volume of mL / kg, respectively. Observations included viability, clinical signs and body weight (days 1 and 10). Blood samples were collected for clinical chemistry (day 0 (before dosing), day 3 and day 10), hematology (day 10) and coagulation (day 10). On day 10, the heart, liver and both kidneys were obtained from each rat and fixed in 10% neutral buffered formalin after weighing.

[0249] Results: There were no drug-related effects on viability, clinical observations, body or organ weights (heart, liver and kidney), clinical chemistry, hematology or coagulation (prothrombin clotting time) parameters.A single subcutaneous administration of 200 mg / kg of compound RD2423 or RD2438 to female Lewis rats was well tolerated. SEQ ID NO:1

Claims

1. A compound comprising a modified oligonucleotide of 14 to 23 linked nucleosides in length having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 10 to 313, 626, 627 and 628.

2. A compound comprising a modified oligonucleotide of 14 to 23 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 313, 626, 627 and 628.

3. A compound comprising a modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 313, 626, 627 and 628.

4. The compound of any one of claims 1 to 3, wherein the nucleobase sequence of the modified oligonucleotide is at least 80%, at least 85%, at least 90% or at least 95% complementary to SEQ ID NO: 1, 3, 5 or 6.

5. The compound of any one of claims 1 to 4, wherein the modified oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase.

6. The compound of any one of claims 1 to 5, wherein the compound is double-stranded.

7. A compound comprising: a first modified oligonucleotide of 14 to 23 linked nucleosides in length having a nucleobase sequence of at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 consecutive nucleobases comprising any one of the nucleobase sequences of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide of 14 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide.

8. A compound comprising: a first modified oligonucleotide of 14 to 23 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide of 14 to 23 linked nucleosides in length having a region complementary to the first modified oligonucleotide.

9. A compound comprising: a first modified oligonucleotide having a nucleobase sequence selected from any one of SEQ ID NOs: 10 to 631; and a second modified oligonucleotide having a length of 19 to 23 linked nucleosides having a region complementary to the first modified oligonucleotide.

10. The compound of any one of claims 7 to 9, wherein the nucleobase sequence of the first modified oligonucleotide has at least 80%, at least 85%, at least 90% or at least 95% complementarity or identity with SEQ ID NO: 1, 3, 5 or 6 over its length.

11. The compound of any one of claims 7 to 10, wherein the core base sequence of the first modified oligonucleotide has at least 1, at least 2, at least 3 mismatches in a region with SEQ ID NO:1, 3, 5 or 6, the region being identical in length to the first modified oligonucleotide.

12. The compound of any one of claims 7 to 11, wherein the length of the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 14 to 23 linked nucleosides.

13. The compound of any one of claims 7 to 11, wherein the length of the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 19 to 23 linked nucleosides.

14. The compound of any one of claims 7 to 11, wherein the length of the complementary region between the first modified oligonucleotide and the second modified oligonucleotide is 21 to 23 linked nucleosides.

15. The compound of any one of claims 7 to 11, wherein the first modified oligonucleotide is fully complementary to the second modified oligonucleotide.

16. The compound of any one of claims 7 to 15, wherein the first modified oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase.

17. The compound of any one of claims 7 to 16, wherein the second modified oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase.

18. The compound of any one of claims 5, 16 and 17, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage.

19. The compound of claim 18, wherein the phosphorothioate internucleoside linkage or the methylphosphonate internucleoside linkage is at the 3' end of the first modified oligonucleotide or the second modified oligonucleotide or at the 5' end of the first modified oligonucleotide.

20. The compound of any one of claims 5, 16, and 17, wherein the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group, and a bicyclic sugar.

21. The compound of claim 20, wherein the modified sugar comprises a 2'-F modification.

22. The compound of claim 20, wherein the modified sugar comprises a 2'-OMe modification.

23. The compound of any one of claims 7 to 15, wherein each nucleoside of the first modified oligonucleotide comprises a modified sugar.

24. The compound of any one of claims 7 to 15, wherein each nucleoside of the second modified oligonucleotide comprises a modified sugar.

25. The compound of claim 23 or 24, wherein the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group, and a bicyclic sugar, or a combination thereof.

26. The compound of claim 25, wherein the modified sugar comprises a modification selected from the group consisting of LNA, cEt, 2'-MOE, 2'-F, 2'-OMe, and 2'-deoxy, or a combination thereof.

27. The compound of claim 23, wherein the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications.

28. The compound of claim 24, wherein the second modified oligonucleotide comprises no more than five 2'-F sugar modifications.

29. A compound as claimed in any preceding claim comprising a conjugated group.

30. The compound of claim 29, wherein the conjugated group is attached to the 5' end of the modified oligonucleotide.

31. The compound of claim 29 or 30, wherein the conjugated group comprises a targeting moiety.

32. The compound of claim 31, wherein the targeting moiety comprises one or more GalNAc.

33. The compound of claim 32, wherein the modified oligonucleotide is the second modified oligonucleotide.

34. The compound of claim 32 or 33, wherein the one or more GalNAc groups are attached to the 2' or 3' position of the ribosyl ring of the 5' nucleoside of the modified oligonucleotide.

35. The compound of claim 34, wherein the 5' nucleoside has the formula: in: R 9 is H, adenine, guanine, thymine, cytosine or uracil, or is adenine, guanine, thymine, cytosine or uracil, each comprising a protecting group (PG), a modified nucleobase, an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl, an optionally substituted heterocyclyl or a nucleobase isostere; L is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a transamide, a carbamate, a carbonate, a urea, an alkyl group, or a heteroalkyl group; R 2 is the oligonucleotide sequence; Y1 is O, CH2, CH2O or optionally substituted NH; Y2 is O, CH2, CH2O or optionally substituted NH; Y3 is CO, SO2, P(O)O, CH2-OC(O), CH2-NH-C(O), CH2-NH-SO2 or CH2; Y4 is CO, SO2, P(O)O, CH2-OC(O), CH2-NH-C(O), CH2-NH-SO2 or CH2; n2 is 0, 1, 2, 3, 4, 5 or 6; and n1, n3, n4 and n5 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

36. The compound of claim 34, wherein the 5' nucleoside is selected from any one of Formulas I to VIII, and wherein R' is S and R is the moiety of the modified oligonucleotide other than the 5' nucleoside.

37. The compound of claim 34, wherein the 5' nucleoside is selected from any one of Formulas I to VIII, and wherein R' is O and R is a portion of the modified oligonucleotide other than the 5' nucleoside.

38. A compound comprising: a first modified oligonucleotide selected from any one of RefID NO: IA0812 to 821; and a second modified oligonucleotide having a length of 14 to 21 linked nucleosides, which is fully complementary to the first modified oligonucleotide.

39. A compound comprising a first modified oligonucleotide selected from the group consisting of Ref ID NO: IA0813 and IA0818, and a second modified oligonucleotide selected from the group consisting of Ref ID NO: IS1002, IS1007 and IS1068.

40. A compound comprising: a first modified oligonucleotide selected from any one of RefID NO: IA0864 to 866; and a second modified oligonucleotide having a length of 14 to 21 linked nucleosides, which is fully complementary to the first modified oligonucleotide.

41. A compound comprising a first modified oligonucleotide selected from the group consisting of Ref ID NO: IA0818 and IA0864, ​​and a second modified oligonucleotide selected from the group consisting of Ref ID NO: IS1058 and IS1059.

42. A compound comprising a first modified oligonucleotide consisting of Ref ID NO: IA0864, ​​and a second modified oligonucleotide consisting of Ref ID NO: IS1059.

43. A compound comprising a first modified oligonucleotide consisting of Ref ID NO: IA0818, and a second modified oligonucleotide consisting of Ref ID NO: IS1058.

44. The compound of any one of claims 1 to 41, wherein the compound is in the form of a pharmaceutically acceptable salt.

45. The compound of claim 42, wherein the pharmaceutically acceptable salt is a sodium salt.

46. ​​The compound of claim 42, wherein the pharmaceutically acceptable salt is a potassium salt.

47. A modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof.

48. The modified oligonucleotide of claim 47, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

49. The modified oligonucleotide of claim 48, which is a sodium salt according to the following chemical structure: or a stereoisomer thereof.

50. A modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof.

51. The modified oligonucleotide of claim 50, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

52. The modified oligonucleotide of claim 51, which is a sodium salt according to the following chemical structure: or a stereoisomer thereof.

53. A modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof.

54. The modified oligonucleotide of claim 53, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

55. The modified oligonucleotide of claim 54, which is a sodium salt according to the following chemical structure: or a stereoisomer thereof.

56. A modified oligonucleotide according to the following chemical structure: or a pharmaceutically acceptable salt or stereoisomer thereof.

57. The modified oligonucleotide of claim 56, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

58. The modified oligonucleotide of claim 57, which is a sodium salt according to the following chemical structure: or a stereoisomer thereof.

59. Compounds according to the following chemical structures: or a pharmaceutically acceptable salt or stereoisomer thereof.

60. The compound of claim 59, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

61. The compound of claim 60 which is a sodium salt according to the following chemical structure: or a stereoisomer thereof.

62. Compounds according to the following chemical structures: or a pharmaceutically acceptable salt or stereoisomer thereof.

63. The compound of claim 62, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

64. The compound of claim 63 which is a sodium salt according to the following chemical structure: or a stereoisomer thereof.

65. A composition comprising the compound or modified oligonucleotide of any one of claims 1 to 64 and a pharmaceutically acceptable carrier.

66. A composition comprising a compound as claimed in any preceding claim for use in therapy.

67. A method for treating, preventing or ameliorating a disease, disorder or condition associated with PKK in an individual, comprising administering to the individual a compound targeting PKK, thereby treating, preventing or ameliorating the disease, disorder or condition.

68. A method of administering a compound or modified oligonucleotide according to any one of claims 1 to 64 or a composition according to claim 65 or 66 to a subject.

69. The method of claim 67 or 68, wherein the disease, disorder or condition is an inflammatory or thrombotic disease, disorder or condition or a symptom thereof, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.

70. The method of any one of claims 67 to 69, wherein administration of the compound inhibits or reduces or ameliorates an inflammatory or thrombotic disease, disorder or condition or a symptom thereof, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.

71. A method for inhibiting PKK expression in a cell, comprising contacting the cell with a compound targeting PKK, thereby inhibiting PKK expression in the cell.

72. The method of claim 71, wherein the cell is in the liver of the individual.

73. The method of claim 72, wherein the individual has or is at risk of having an inflammatory or thrombotic disease, disorder or condition or a symptom thereof, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.

74. A method of reducing or inhibiting an inflammatory or thrombotic disease, disorder or condition or symptoms thereof, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in an individual, comprising administering to the individual a compound targeting PKK, thereby reducing or inhibiting an inflammatory or thrombotic disease, disorder or condition or symptoms thereof, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelid, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction in the individual.

75. The method of claim 74, wherein the individual has or is at risk of having an inflammatory or thrombotic disease, disorder or condition or a symptom thereof, hereditary angioedema (HAE), edema, angioedema, swelling, eyelid angioedema, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.

76. The method of any one of claims 67 to 75, wherein the compound is a compound that targets PKK.

77. The method of any one of claims 67 to 76, wherein the compound is a compound of any one of claims 1 to 64 or a composition of claim 65 or 66.

78. The method of claim 77, wherein the compound or composition is administered parenterally.

79. Use of a compound targeting PKK for treating, preventing or ameliorating a disease, disorder or condition associated with PKK.

80. The use of claim 79, wherein the disease, disorder or condition is an inflammatory or thrombotic disease, disorder or condition or a symptom thereof, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.

81. The use of claim 79 or 80, wherein the compound is a compound targeting PKK.

82. The use of any one of claims 79 to 81, wherein the compound is a compound of any one of claims 1 to 64 or a composition of claim 65 or 66.

83. Use of a compound targeting PKK in the preparation of a medicament for treating, preventing or ameliorating a disease, disorder or condition associated with PKK.

84. The use of claim 83, wherein the disease is an inflammatory or thrombotic disease, disorder or condition or a symptom thereof, hereditary angioedema (HAE), edema, angioedema, swelling, angioedema of the eyelids, ocular edema, macular edema, cerebral edema, thrombosis, embolism, thromboembolism, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or infarction.

85. The use of claim 83 or 84, wherein the compound is a compound targeting PKK.

86. The use of any one of claims 83 to 85, wherein the compound is a compound as described in any one of claims 1 to 64 or a composition as described in claim 65 or 66.

87. The method or use of any of the preceding claims, wherein the compound or composition is administered to the subject from about once every three months to about once per year.

88. The method or use of any of the preceding claims, wherein the compound or composition is administered to the subject about once every three months, about once every six months, or about once a year.

Citation Information

Patent Citations

  • Modified RNAi agents

    US10668170B2

  • Conjugated antisense compounds and their use

    US10844379B2

  • Lipid-based formulations

    US20030077829A1

  • Ligands to enhance cellular uptake of biomolecules

    US20030119724A1

  • Nuclease resistant chimeric oligonucleotides

    US20030158403A1